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Background: Lung cancer is a main cause of death in patients suffering from COPD and 
smokers with COPD have an increased risk of lung cancer compared to healthy smokers. 
COPD comprises a broad range of features, including emphysema, chronic bronchitis, 
asthmatic features, and acute exacerbations in COPD (AECOPD). We hypothesized that 




1. To explore if emphysema and airway wall thickness assessed quantitatively on 
CT increase the risk of lung cancer and non-pulmonary cancer. 
2. To investigate if acute exacerbations in COPD are associated with the risk of lung 
cancer, and to see whether this association differs based on coexisting asthma. 
3. To examine and compare two lung cancer screening scores in our population of 
patients with COPD. 
 
Materials and Methods: Participants included in the analyses of all three papers were 
from the GenKOLS study in Bergen, Norway, conducted between January 2003 and 
January 2005. Participants were 40-85 years of age and had a smoking history of at least 
2.5 pack-years at baseline. GenKOLS was conducted as a case-control study. COPD 
was diagnosed when post-bronchodilator FEV1/FVC was <0.70 and FEV1<80% 
predicted. Baseline examinations included a detailed questionnaire on smoking habits, 
respiratory symptoms, and disease history, as well as pulmonary function tests. 
Approximately half of all the participants had a chest CT scan. Baseline data were linked 
to incident cancer data from the Cancer Registry of Norway throughout the year 2013. 
All subjects with a cancer diagnosis before inclusion were excluded from the analyses. 
In Paper III, the subjects were divided into high and low risk according to the National 
Lung Cancer Screening Trial (NLST) inclusion criteria, and the COPD-Lung Cancer 








1. After adjustment for age, sex, pack-years, age of onset of smoking, smoking 
status at baseline, and FEV1, the baseline amount of emphysema remained a 
significant predictor of the incidence of non-pulmonary cancer and lung cancer. 
Airway wall thickness did not predict cancer independently.  
2. AECOPD was significantly associated with lung cancer during ten years of 
follow-up only in COPD patients without asthma. The analysis was adjusted for 
sex, age, smoking variables, FEV1, and BMI.  
3. The NLST selection criteria, and the COPD-LUCSS were both significantly 
associated with the risk of lung cancer. The area under the curve values showed 
that both models have poor discriminatory abilities in our cohort. There was no 
significant difference in the discriminatory ability between the scores. 
 
Conclusions: Some features of COPD were significantly associated with the risk of lung 
cancer, and even non-pulmonary cancer. Emphysema was significantly associated with 
lung cancer risk and risk of non-pulmonary cancer, whereas airway wall thickness was 
not. AECOPD was associated with an increased risk of lung cancer only in COPD 
patients without asthma. Some of these features of COPD might be of use in evaluating 
those who could benefit from lung cancer screening. 
Although both the NLST selection criteria and the COPD-LUCSS, were associated with 
an increased risk of lung cancer, both scores had poor discriminatory abilities in our 
cohort of COPD patients. More studies are needed to find better models to target those 
at higher risk of lung cancer. 
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Terms and Abbreviations 
AECOPD                  Acute Exacerbation in Chronic Obstructive Pulmonary Disease 
 
ATS                          American Thoracic Society 
 
AUC             Area Under the Curve 
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BMI                          Body Mass Index 
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COPD                       Chronic Obstructive Pulmonary Disease 
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HCRHS                   Hordaland County Respiratory Health Survey 
 
HR                           Hazard Ratio 
 
HU                           Hounsfield Units. A density scale, ranging from -1000 HU  
(equivalent of air) to + 1000 HU (equivalent of dense bone). Water has 
a density of 0 HU. 
 
HUH                        Haukeland University Hospital 
 
ICS                          Inhaled Corticosteroids 
 
kVp                          kilo-Volt peak. Beam energy 
 
LDCT                      Low Dose CT 
 
LLN   Lower Limit of Normal 
 
MMP                       Matrix Metalloproteinase 
 
NLST                      National Lung Cancer Screening Trial 
 
NPV                        Negative Predictive Value 
 
OR                          Odds Ratio 
 
Pack-years              Number of cigarettes smoked per day divided by 20, multiplied  
with the number of years smoked 
 
PPV                          Positive Predictive Value 
 
ROC                         Receiver Operating Curve 
 





SOHAS                    Second Oslo and Hordaland Asthma Survey 
 
Voxel                        A three-dimensional pixel, or a box. The size of a voxel is  
decided by the resolution of the image and the slice thickness. A voxel 
is the smallest part of the lung where individual density measurements 
can be made using quantitative CT. 
 
%LAA             Percentage Low Attenuation Areas. A measure of the degree of 
emphysema. Indicates the relative amount of lung voxels that has a 
density less than a given cut-off. The cut-off used in the analyses of this 
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Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung disease 
representing a significant burden for individuals and society. According to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) report of 2020, COPD is the 
fourth leading cause of death worldwide and is expected to be the third in the near future 
(1). Estimated deaths from COPD in 2015 was 3.2 million people worldwide, an 
increase of 11.6% compared to 1990 (2). COPD is also a substantial cause of morbidity, 
and many patients die prematurely from either the disease itself, related complications, 
or its correlated comorbidities. Comorbidities, defined as the coexistence with other 
diseases, are often seen in patients with COPD. One of these comorbidities is lung 
cancer. COPD patients are shown to have an increased risk of lung cancer compared to 
healthy smokers (3). COPD comprises a wide spectrum of features or phenotypes, 
including emphysema, chronic bronchitis, asthmatic features, and an acute exacerbation 
in COPD (AECOPD). Lung cancer is a leading cause of death in patients with COPD 
(1, 4). Due to a lack of symptoms in the early stages of the disease, lung cancer is often 
discovered at advanced stages with poor prognosis (5). This has led to an extensive 
debate on lung cancer screening. Several studies aim to identify individuals at higher 
risk of lung cancer in smokers (6).  
 
In this chapter, I will shortly present relevant background on COPD, including burden, 
diagnosis, and different features of COPD. Then I will present current knowledge on 
some features in COPD related to lung cancer and non-pulmonary cancer, followed by 
an introduction to lung cancer screening.  
 
 
1.1. Chronic obstructive pulmonary disease 
Permanent respiratory symptoms and airflow-limitation characterize COPD. Symptoms 
arise due to changes in the airways and the alveoli, usually due to significant exposure 
to noxious particles or gases, of which smoking is the most important. Other factors 




chemicals. COPD can also be developed due to genetic predisposition, such as alfa1-
antitrypsin deficiency. Dyspnea, chronic cough, and phlegm are the most common 
respiratory symptoms. COPD comprises a broad range of manifestations that overlap 
with entities such as emphysema, chronic bronchitis, asthmatic features, and an acute 
exacerbation in COPD (AECOPD), all of which will be addressed later in this section. 
 
1.1.1. Burden 
The worldwide prevalence of COPD varies extensively, mainly due to differences in age 
and tobacco exposure (7). Differences in diagnostic criteria, study design, and diverse 
population demographics make it difficult to compare various estimates, such as 
prevalence (8). The Burden of Obstructive Lung Diseases (BOLD) and other large 
epidemiological studies have estimated that 384 million persons were affected in 2010, 
which correspond to a global prevalence of 11.7% (9). In Norway, the number was 
estimated to be 150 000 persons in 2018, which corresponded to 6% of those above 40 
years (10). The total number of affected people worldwide is expected to grow in the 
coming years due to an increasingly aging population and also due to increasing tobacco 
consumption in developing countries (11). COPD causes an enormous economic and 
social burden. In the United States, COPD was estimated to cost 32 billion dollars 
directly and 20.4 billion in indirect costs in 2010 (12). A Norwegian study from 2009 
estimated the treatment-related cost of COPD in Norway in the year 2005/2006 to be 
105 million euro (13). In developing countries, the primary cost is related to loss of 
working ability. Often, not only the person directly affected will need to stop working, 
but also the family members who take care of the patient (14).  
 
1.1.2. Diagnosis 
According to the GOLD report, a COPD diagnosis should be considered in a person who 
presents with dyspnea, chronic cough or phlegm, or a history of exposure to risk factors 
(15). A detailed medical history is necessary, and a physical examination is useful to 
sort out other reasons for the symptoms. Spirometry is needed to make the diagnosis in 
a clinical setting (16). How spirometry is done and values such as forced vital capacity 




Methods section. The measurements are evaluated by comparison to reference values 
based on sex, age, height, and ethnicity. FEV1 and FVC are presented as percent 
predicted of these reference values. A post-bronchodilator FEV1/FVC<0.70 is required 
to confirm persistent airflow limitation and indicates COPD in a patient with fitting 
symptoms and sufficient exposure to noxious particles (15).  
 
1.1.3. Features   
COPD comprises various clinical manifestations, aspects, features, or phenotypes. 
According to Han et al., phenotypes of COPD refer to one or more disease features that 
can distinguish patients suffering from COPD based on clinically significant aspects 
(17). The Spanish COPD guideline introduced four phenotypes based on exacerbation 
frequency and dominant clinical manifestations, such as emphysema, bronchitis, and 
bronchial asthma (18). To this date, there is no worldwide consensus concerning which 
phenotypes of COPD should be included and how they should be defined. Therefore, I 
will use the term features when addressing clinical aspects of COPD in this thesis.  
Chronic bronchitis, emphysema, asthma, and frequent exacerbations can coexist in 
different combinations. The scientific environment is in continuous development when 
it comes to investigating different features of COPD and their importance in treatment 
and pathophysiology.  
 
1.1.3.1. Emphysema 
Emphysema is the destruction of the alveoli, the surface in the lungs where gas exchange 
occurs. Structural changes found in emphysema appear as permanent and abnormal 
enlargement of the airspaces distal to the terminal bronchioles, accompanied by 
destruction of the airspace walls. Emphysema is most commonly seen in patients with 
moderate to severe airflow obstruction but can also occur in people with little or no 
airflow obstruction (19). Emphysema is best detected on computed tomography (CT) of 
the chest. The methodology of CT detected emphysema varies and can be divided into 
qualitative or visual and quantitative or automated assessed emphysema. Qualitatively 
assessed emphysema is interpreted visually by trained radiologists, whereas 





1.1.3.2. Chronic bronchitis 
Chronic bronchitis is diagnosed by a chronic productive cough for three months in each 
of two succeeding years, where other causes of chronic cough have been excluded (20). 
 
1.1.3.3. Asthma and asthma-COPD overlap 
Asthma is another chronic disease, obstructing the airways. It is separated from COPD 
because the airflow obstruction often is reversible either spontaneously or with treatment 
(21). Asthma is characterized by recurrent episodes of wheezing, breathlessness, 
tightening of the chest, and coughing. Patients with asthma might develop COPD (22). 
Some of the COPD patients have clinical features similar to those in asthma. This mixed 
phenotype has been referred to as ACOS (Asthma-COPD Overlap Syndrome) and is 
defined by features shared with both asthma and COPD (23).  
 
1.1.3.4. Acute exacerbations 
An acute exacerbation in COPD can be defined as “an acute event characterized by a 
worsening of the patient’s respiratory symptoms that is beyond normal day-to-day 
variation” (1). However, there is to this date no consensus as to how AECOPD should 
be defined. Some definitions are mainly based on symptoms, others on the need for 
healthcare resources, and some both (24). The definition by Anthonisen et al. is one of 
the most cited definitions of AECOPD (25). The definition describes three levels of 
exacerbations based on the presence of symptoms. Type 1, all of the following 
symptoms present: increased dyspnea, sputum volume, and sputum purulence. Type 2, 
two of the mentioned symptoms present, and type 3, one of the symptoms, and at least 
one additional criteria; upper respiratory infection within the past five days, fever 
without other cause, increased wheezing or cough, and an increase in respiratory rate 
or heart rate by 20% compared with baseline (25). AECOPD is associated with 
increased hospitalization and mortality. Viruses and bacteria are thought to cause most 




Some of these specific features might more often coexist with different comorbidities, 




Due to common risk factors like smoking, aging, alcohol, diet, and inactivity, 
comorbidities such as cardiovascular disease, skeletal muscle dysfunction, metabolic 
syndrome, osteoporosis, depression, anxiety, and lung cancer are often seen in patients 
with COPD (28). Comorbidities have a significant impact on the prognosis of COPD 
(29). Risk factors and symptoms of COPD might be shared with some of its 
comorbidities and serve as a link between COPD and other diseases (30). For instance, 
the existence of COPD may increase the risk of lung cancer (31). Whether COPD 
increases the risk of cancer outside the lungs as well remains mostly unknown. 
 
1.2.1. COPD, lung cancer and non-pulmonary cancer 
Cancer represents a large group of diseases in which abnormal cells overgrow and 
possess the ability to invade nearby tissue and distant locations through the blood and 
lymph system (32). Cancer cells can arise in any part of the body, and cancer is the 
second leading cause of death globally. Cancer was responsible for approximately 9.6 
million deaths in 2018. An estimated 1.8 million deaths occurred due to lung cancer 
globally in 2018 (33), and 2236 in Norway the same year (34). Extensive evidence 
supports an association between COPD and lung cancer (4). Even though tobacco 
exposure is said to be accountable for 90% of all lung cancer cases (35) and represents 
the leading cause of COPD, lung cancer and COPD coexist more frequently than 
expected if they were to be independently triggered by smoking (36). Impaired lung 
function has shown to be associated with increased lung cancer risk, adjusted for 
smoking (37-39). Emphysema is the strongest known imaging biomarker for lung cancer 
(37). However, conflicting results exist regarding quantitatively assessed emphysema 
and the risk of lung cancer (38-41). Also, the relationship between AECOPD and lung 





Tobacco use is associated with an increased risk of several cancer types (42) and is 
responsible for an estimated 22% of cancer deaths (42, 43). Smoking is a significant 
cause of inflammation (44), and chronic inflammation is considered an essential part of 
lung cancer pathogenesis in COPD patients (45). COPD is considered a systemic disease 
(46), and the  systemic inflammation might imply a higher risk of non-pulmonary cancer 
in at least some COPD patients. Whether emphysema or airway wall thickness (AWT) 
is associated with cancer outside the lungs, remains unknown.  
 
 
1.3. Relevant literature  
There was a need for clarification concerning whether some features of COPD are linked 
to lung cancer and non-pulmonary cancer. We, therefore, performed a literature review 
examining the associations between CT assessed emphysema as well as AWT and 
cancer risk. A separate literature review was done examining AECOPD and lung cancer, 
and summary articles were read regarding the role of asthma and lung cancer. 
Recent efforts have been made to identify COPD patients who could benefit from lung 
cancer screening. Some suggest the use of COPD status, airway obstruction, or CT 
detected emphysema as risk factors to better target the population at highest risk (47-
49). Key literature on lung cancer screening was also reviewed prior to the start of the 
current thesis. 
 
1.3.1. Features of COPD and the risk of cancer 
A PubMed search was performed with the keywords: “emphysema and lung cancer”. 
This yielded 969 papers from January 2000—June 2016, of which all titles were read. I 
read the abstracts where the titles contained “emphysema” and “lung cancer”, “COPD” 
and “lung cancer” or other lung disease and “lung cancer” and downloaded the full text 
of twenty-eight papers after reading the abstracts. Only nine papers used CT detected 
emphysema as opposed to patient-reported emphysema, and these were included in the 
overview of lung cancer and emphysema (Table 1). Searches for cancer outside the 
lungs and COPD or emphysema were also performed, giving one relevant result by June 




done in February 2020 on “COPD exacerbations and lung cancer,” which resulted in 
248 papers from 2000—2019. All titles were read, but only seven papers were saved 
after reading relevant abstracts. Only two were directly relevant.  
 
Conflicting results exist regarding emphysema assessed on computed tomography (CT) 
and the risk of lung cancer. Several studies have found an increased risk of lung cancer 
by visually or qualitatively assessed emphysema (41, 50-52), whereas not for automated 
or quantitatively assessed emphysema (38-40). Several of these were cross-sectional 
studies examining emphysema and lung cancer at the same time and were not able to 
conclude regarding cause and effect. Another problem when comparing the studies 
using quantitative measurements is the lack of a standard protocol for the measurements 
and a common consensus on how much emphysema is considered normal.  
 
One Danish cohort study (53) found that COPD patients had an increased risk of several 
smoking-related cancers compared to individuals without COPD. They lacked data on 
tobacco consumption and were not able to adjust for smoking.  
 
AWT and risk of lung cancer was examined in a case-control study, including 117 
matched pairs of lung cancer cases and controls sampled from a screening trial (40). 
They did not observe any relationship between airway wall thickness and the risk of 
lung cancer. 
 
Only two studies have examined AECOPD and the risk of lung cancer (54, 55). COPD 
patients with incident lung cancers had more exacerbations 12 months before baseline 
in a case-control study from the COPDGene cohort (55). In a study of 433 COPD 
patients and 279 healthy controls, AECOPD was not related to increased incidence of 
lung cancer during nine years follow-up (54). Often patients with coexisting asthma 
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One study examining risk factors for lung cancer in COPD found that coexisting asthma 
had a protective effect. This study did not adjust for pack-years of smoking, nor lung 
function, which can explain reduced lung cancer risk with coexisting asthma (56).  
Studies exploring asthma and lung cancer risk in non-COPD populations have given 
conflicting results. One meta-analysis found that self-reported asthma increased the risk 
of lung cancer, whereas a doctor’s diagnosis did not (57). 
 
1.3.2. Lung cancer screening 
In the 1980s, it was concluded that screening for lung cancer with sputum cytology and 
chest radiography did not improve mortality (58, 59). Due to these findings, there was a 
long break in lung cancer screening research. In 1999, chest CT was used for diagnosis 
and led to a new interest in the field (60). Most clinicians agree that early detection of 
lung cancer is beneficial, but it remains unclear whom to screen, how often, and how to 
follow up. A large proportion of false-positive findings and high costs are among the 
challenges (61). In November 2017, Oudkerk et al. published a European position 
statement on lung cancer screening (61). They stated that a correct selection of a target 
population was essential and that the population could not be selected based on age 
alone, as in many other cancer screening programs. This was due to substantial risk 
factors such as tobacco smoke. Most randomized control trials (RCTs) performed 
between 2002—2014 (62-70) had recruitment criteria exclusively based on age and 
magnitude of tobacco smoking. Wille et al. (63) included FEV1>30% and performance 
status in their recruitment criteria but did not find that CT screening improved lung 
cancer mortality. Field et al. included a risk score for lung cancer incidence based on 
several factors (69). Since most RCTs based on age and smoking consumption alone 
have given conflicting results, many multivariable risk prediction models have been 
published (71-74), trying to improve predictive abilities. None of the RCTs, nor these 
prediction models, were made in a population of COPD patients, even though several 







1.3.2.1. The NLST and the COPD-LUCSS 
To determine whether low-dose CT could reduce lung cancer mortality, the NLST (66) 
enrolled 53 454 participants at high risk of lung cancer at 33 different medical centers 
in the United States from August 2002 through April 2004 (66). The participants were 
randomly assigned to either undergo three annual regular chest X-rays or three annual 
CT scans. Data on lung cancer cases and lung cancer deaths were collected through 
2009. Inclusion criteria were based on age and smoking history and will be presented in 
the Methods section (Table 4). The NLST observed that the use of low-dose CT (LDCT) 
reduced lung cancer mortality by at least 20%. Even though the NLST concluded that 
their data alone were not sufficient to fully inform important decisions on whether or 
not to recommend screening, some guidelines on screening programs recommend using 
LDCT of the chest mainly based on the results from the NLST (75). 
 
Several studies have tried to improve the screening criteria since the results from the 
NLST were published (73, 74, 76, 77). De Torres et al. created a lung cancer screening 
score for COPD patients, COPD-LUCSS, and validated and compared it to the NLST 
selection criteria in another population (76). Their score included information on body 
mass index (BMI), pack-years, age, and emphysema (Table 4). They concluded that 
their score predicted lung cancer in patients with COPD better than the NLST selection 
criteria. De Torres et al. compared their score to the NLST selection criteria by visual 
comparison of Kaplan-Meier plots without an objective statistical test. They did not 
present the discriminatory abilities of either two scores (76).  
 
 
1.4. Summary of introduction 
In summary, there was a need for clarification concerning the association between 
different features of COPD and lung cancer risk. We hypothesized that emphysema and 
AWT increased the risk of lung cancer. With COPD being considered a systemic 
disease, we further hypothesized that emphysema and AWT were associated with 




was associated with lung cancer risk, and that there was a difference in the effect of 
AECOPD on lung cancer based on coexisting asthma.  
 
After the publication from the NLST by Aderle et al., lung cancer screening was 
recommended by several guidelines despite numerous unsolved problems. De Torres et 
al. claimed to have found an improved lung cancer screening score for COPD patients. 
Both the NLST selection criteria and the COPD-LUCSS need to be evaluated 
objectively in a more representative COPD population.  
 
We had access to a community-based cohort of subjects with and without COPD with 
detailed information regarding smoking habits, lung function, disease history, and 
quantitatively interpreted CT scans of the chest. These data were linked to reliable 


























To investigate if level of emphysema and AWT assessed quantitatively on CT 





To explore whether an acute exacerbation in COPD was associated with an increased 
risk of lung cancer, and to examine whether the effect of AECOPD on lung cancer 




To examine and compare the discriminatory ability of two lung cancer screening scores, 
























3. Methods  
 
This thesis is based on data from the GenKOLS study conducted in Bergen, Norway, 
between 2003 and 2005. Details on the study population, study design, and data 
management will be presented, followed by key information about the main variables, 
and an introduction to the statistical analysis done in all three papers.  
 
 
3.1. Study population and study design 
The GenKOLS study took place at Haukeland University Hospital (HUH) and was 
sampled as a case-control study to examine genetic and environmental factors in 
COPD. Cases had COPD, defined as post-bronchodilator FEV1/FVC <0.70 and FEV1 
<80% predicted. Controls had post-bronchodilator FEV1/FVC >0.70 and FEV1 >80% 
predicted. The examination at baseline in 2003/05 included an extensive questionnaire, 
including questions on smoking habits, respiratory symptoms, and disease history. 
Participants performed pulmonary function tests, and about half of them did an 
optional CT scan. The data from GenKOLS were linked to data from the Cancer 
Registry of Norway (78) with complete data from 2003 through 2013. The prospective 
study design enabled us to investigate variables at baseline and effect ahead in time. 
 
The subjects included in the analyses of Paper I consisted of cases and controls that had 
a chest CT examination (Table 2). For Paper II, we included all cases. And finally, in 
Paper III, the sample was restricted to cases with a chest CT. 
 
3.1.1. The GenKOLS population (Table 2) came from four sources (79)  
1. Hordaland County Respiratory Health Survey (HCRHS)  
2. Second Oslo and Hordaland Asthma Survey (SOHAS)  
3. Haukeland University Hospital COPD registry (HUH COPD registry)  





The HCRHS was conducted in 1985 and was a large population cohort based on simple 
randomization of the population between 15 and 70 years old in Hordaland county, 
Norway (80). Those still living in Bergen and surrounding municipalities were invited 
to participate in one follow-up in 1996 and another follow-up in 2003-2005 (81, 82). 
The participants who fulfilled the GenKOLS inclusion criteria were invited to 
participate there as well. SOHAS was performed in Oslo and Hordaland county in 1998 
and was a cross-sectional study, including a random sample of inhabitants aged 15-70 
years (83). The HUS COPD registry included all patients registered with a COPD or an 
emphysema diagnosis between 1997 and 2005. The group of volunteers was people who 
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3.1.2. Inclusion and exclusion criteria in GenKOLS  
Inclusion criteria  
- Able and willing to sign an informed consent form. 
- Age ³ 40 years. 
- Current or ex-cigarette smoker, minimum 2.5 pack years. 
- No evidence of severe a1-antitrypsin deficiency (ZZ, Z Null, Null-Null, or SZ) 
assessed by PI type. 
- Caucasian – self-reported 
 
Exclusion criteria 
- Unable to give informed consent. 
- Severe anemia as defined by hemoglobin of the same or < 9.0 g/dl. 
- Known HIV, hepatitis B or C infection 
- Blood transfusion received within last four weeks. 
- Chronic pulmonary disorder other than COPD (e.g., lung cancer, sarcoidosis, 
active tuberculosis, and lung fibrosis.) Inactive tuberculosis and previous 
diagnosis of asthma were not an exclusion criterion. 
- Status post-lung or other organ transplantation. 
- Status post-lung volume reduction surgery. 
- Taken antibiotics for respiratory disease within one month or have had a 
respiratory infection within six weeks of the visit. 
Participants who fulfilled transient exclusion criteria such as low hemoglobin or recent 
respiratory infections were reconsidered for inclusion at a later date. 
 
In this thesis, all subjects with a cancer diagnosis of any kind, before inclusion in 
GenKOLS, were excluded. Also, those who emigrated during follow-up were omitted 







3.1.3. Study sequence and data collection  
All study participants received an invitation with an explanation of the study, a screening 
consent form, a screening questionnaire (Appendix A, B), and an appointment for a 
screening visit and clinical examination at HUH (79). At the screening visit, information 
about the study was given, and all participants signed an informed consent form. The 
screening questionnaires were completed and checked. Weight and height were 
measured. All participants underwent pre-bronchodilator spirometry, then case-control 
questionnaire part 1 was filled out before post-bronchodilator spirometry. Based on the 
spirometry and screening questionnaire, the participants were identified as either cases 
or controls. Only those who fulfilled the inclusion criteria continued with further 
examination and signed an additional informed consent form (Appendix C). They 
answered the case-control questionnaire, part 2 covering smoking history, medical 
history, and more. The wording was based on previously validated studies (84). The 
questions that were used in Paper I-III are printed in Appendix D of this thesis. Also, an 
optional high-resolution CT scan for quantitative analyses was offered until a total of 
approximately 1000 CTs were taken. These were equally distributed between cases and 
controls (79). 
 
3.1.4. Data management 
The data obtained from questionnaires and clinical tests were recorded on paper and 
kept in a locked archive before it was punched into an online database. Continuous error-
checks were applied to reveal and correct punching errors, such as missing values and 















AECOPD was defined as an antibiotic course taken due to lung disease in the last 12 
months preceding inclusion. The question asked was, “Have you had treatment with 
antibiotics for lung disease during the last 12 months?” and “If YES, how many times?”  
 
3.2.2. Asthma 
Participants were considered to have a history of asthma if they gave affirmative answers 
to both, “Have you had asthma?” and “If yes, was this confirmed by a doctor?” 
 
3.2.3. Spirometry 
A spirometer measures the lung function as the volume of air being inhaled and exhaled 
in a certain amount of time, enabling a calculation of flow. The measurements in 
GenKOLS were done using a Vitalograph 2160 Gold Standard Plus (Appendix E),  
according to the American Thoracic Society (ATS) standards (85). The spirometric 
measurements were recorded at the screening visit at least six weeks after any airway 
infections. The participants were not asked to abstain from daily medication (79). 
Trained technicians conducted the pulmonary function tests. Both pre-bronchodilator 
and post-bronchodilator tests were conducted. The post-bronchodilator tests were 
performed 30 minutes after receiving 400 microgram Salbutamol via metered-dose 
inhaler and Aerochamber spacer. Three acceptable maneuvers were recorded, and the 
highest values were selected.  
 
Two parameters were evaluated from spirometry, the FVC, and the FEV1. The FVC 
refers to the amount of air that by force can be exhaled from the lungs from a point 
where the lungs are maximally filled. The FEV1 is defined as the amount of air exhaled 
the first second. In healthy lungs, the amount of air forced out the first second represents 
a large portion of the total FVC. When lungs are obstructed, as in COPD, less air can be 
forced out in the first second. The measurements are evaluated by comparison to 




as % predicted. Local reference values for FVC and FEV1 were used (80). The post-
bronchodilator values were used in the statistical analyses. 
 
 
3.2.4. CT, emphysema, and AWT definition 
The high-resolution CT images were acquired at Haukeland University Hospital with a 
GE LightSpeed Ultra CT scanner (120 kVp, 200 mA; GE Healthcare, Milwaukee, WI, 
USA) at full inspiration using 1.25-mm slice thickness at 20 mm intervals from the apex 
to the base of the lung (Appendix F). The quantitative analysis of the CT images was 
performed by the iCapture Centre in Vancouver, BC, Canada, under the supervision of 
Dr. Harvey Coxson (UBC James Hogg Research Centre and Vancouver General 
Hospital). Details on the CT scanning are presented in another thesis (79). The extent of 
emphysema was assessed quantitatively by a software developed by the iCapture Centre 
and was obtained using the percentage of lung voxels with X-ray attenuation values 
below – 950 Hounsfield units (HU). HU represents a density scale, ranging from -1000 
HU (the equivalent of air) to + 1000 HU (the equivalent of dense bone). Water has a 
density of 0 HU. The – 950 HU has shown to be appropriate for measuring emphysema 
with this CT acquisition technique (86). The term %LAA (percentage low attenuation 
areas) was used to describe these low-density regions. The percentage of emphysema 
for the whole lung was calculated. The AWT was calculated by taking the square root 
of the wall area for each measured airway, plotted against the internal perimeter of that 
airway. AWT was presented for a standardized airway with an internal perimeter of 10 
mm, AWT-Pi10 (87). Details on AWT are presented in another thesis (79). 
 
 
3.2.5. Lung cancer screening scores 
In Paper III we divided the sample into groups of high and low risk according to two 









Table 4. Variables included in the COPD-LUCSS (76) and the NLST selection 
criteria (66). 
 
COPD-LUCSS   
BMI <25   1 point 
Pack-years history >60   2 points 
Age >60 years-old   3 points 
Radiological Emphysema: yes   4 points 
Total 10 points 
COPD-LUCSS: Chronic Obstructive Pulmonary Disease – Lung Cancer Screening Score 
The low risk category included those with 0-6 points. The high risk category includes those with 7-10 points. 
 
 
NLST inclusion criteria   
Pack years >30 
 
Age 55-74 years. 
 
Current smoker or quit smoking within the previous 15 years 
NLST: National Lung Cancer Screening Trial 
Those with all the mentioned criteria are considered as high risk. Those with two or less of the mentioned criteria 
are considered low risk. 
 
 
3.2.6. Norwegian national identity numbers 
Every person registered in the Norwegian National Registry has a national identity 
number of 11 digits. It is a personal identifier that each person receives from birth or 
when they settle in Norway (88). This number follows the person in all hospital visits 
and is used in several national registries. This number enabled us to combine data from 
different registries.  
 
3.2.7. Cancer Registry of Norway  
Lung cancer was the primary outcome in all three papers, and non-pulmonary cancer a 
primary outcome in Paper I. Cancer diagnosis were obtained from the Cancer Registry 
of Norway (89). The Cancer Registry of Norway was established in 1952 and has since 
then systematically collected cancer occurrence in Norway. The registry is considered 
to be close to complete from 1953, and a data quality study found  98.8% completeness 
for the period 2001–2005 (78). In September 2019, the incidence registry contained 
information on 1 984 415 cases in 1 574 700 individuals (34). The Cancer Registry also 
receives data from the Cause of Death Registry to ensure the validity of the data and 




ICD-10-code C34, and non-pulmonary cancers were defined as all cancers outside the 
lung. We obtained data from January 2003 through December 2013 for the study 
participants. Data included cancer histology and the time of diagnosis. 
 
3.2.8. Norwegian Cause of Death Registry  
All deaths in Norway are registered in the Cause of Death Registry, run by the 
Norwegian Institute of Public Health (90). We received data from January 2003 through 




All analyses were performed with STATA (Stata Statistical Software: release 13-16; 
StataCorp, College Station, TX, USA). The two-sided significance level was 
conventionally set to 0.05 for all analyses in all three papers.  
 
3.3.1. Paper I  
AWT measured as AWT-Pi10 and emphysema measured as %LAA were the main 
predictors of interest when investigating the risk of lung cancer and non-pulmonary 
cancer. With the lack of a suggested classification of %LAA stages, the degree of 
emphysema was categorized in the same way as in another paper from our group using 
the same cohort (91). The emphysema groups were based on visual inspection of a 
quantile plot. Most participants had %LAA under 3% (60%). A rise occurred between 
the 60th and 80th percentile, and a steep rise was seen from the 80th percentile. The 
emphysema groups were, therefore, categorized as follows, low emphysema as %LAA 
under 3%, medium as %LAA from 3-10%, and high as %LAA above 10%. Low 
emphysema was considered well within the normal range. The normal range was based 
on the 95th percentile of the non-COPD participants still alive after a follow-up period 






Kaplan-Meier plots provided a visual presentation of the emphysema groups and time 
to a cancer diagnosis (92). We used Cox proportional hazards regression to estimate 
hazard ratios (HR) for the effect of emphysema and AWT on cancer diagnosis over time. 
The models were adjusted for sex, age, pack-years, age of onset of smoking, smoking 
status at inclusion, and FEV1, which were considered clinically relevant confounders. 
 
 
3.3.2. Paper II  
AECOPD was the main predictor and was analyzed as a dichotomous variable (0 vs. 1 
or more exacerbations). Kaplan-Meier methods were used to calculate and plot 
probabilities for developing lung cancer. We performed Cox proportional hazards 
regression to quantify differences in the risk of developing lung cancer. In this thesis the 
hazard ratios are presented as HR, in the submitted paper, we used the term HRR (hazard 
rate ratio) for the same values (Paper II). We tested for the interaction between AECOPD 
and asthma on lung cancer to explore whether this effect differed based on coexisting 
asthma. Relevant covariates were adjusted for in the model, including sex, age, pack-
years, age of onset of smoking, smoking status at inclusion, body mass index (BMI), 
and FEV1.  
To account for mortality as a competing risk, we also performed Fine and Gray 
competing risk analyses for the probability of developing cancer (93). The Fine and 
Gray competing risk regression model is often used as an alternative to Cox regression 
when competing risks are present. In competing-risks regression, the focus is on the 
cumulative incidence function (CIF), indicating the probability of experiencing an event 
before a given time. Cox regression, on the other hand, gives estimates for the cause-
specific risk (hazard) to have the event (94). In Cox regression, competing risks, such 
as mortality, are typically censored, and the risk of an event is assumed to be equal for 
censored and non-censored individuals. In competing risk, a competing risk preceding 
the event of interest will change the probability of having the event of interest. The 
results from the Fine and Gray Competing risk model (93) were presented as sub-hazard 





3.3.3. Paper III 
De Torres et al. (76) claimed to have developed a lung cancer screening score better 
than the inclusion criteria presented by the NLST, but did not present statistical tests to 
objectively compare the two scores. We have used several methods to compare the two 
scores, some of which will require more detailed background information. 
An ideal score or model will always be able to classify those who will develop the 
disease in one category, and those who will not develop the disease in another. A 
model’s ability to do just that can be described by both discrimination and calibration. 
The discriminatory ability of a model refers to its ability to separate those at high risk 
from those at low risk of an event (95). Calibration is the model’s ability to produce 
accurate estimates or predicted risks close to the actual observed risk. Both 
discrimination and calibration are crucial tools to investigate the predictive ability of a 
model (96). Discrimination for binary events such as lung cancer or no lung cancer can 
be measured using receiver operating characteristic (ROC) or C statistics. It is, however, 
important to emphasize that C-index is influenced by follow-up time. The same follow-
up time is necessary to compare the C-index in two models (95). The discriminatory 
ability of both the NLST selection criteria and the COPD-LUCSS was poor in our study. 
A predictive model with poor discriminatory ability will not be of any use even with 
proper calibration. Hence, we did not assess calibration herein.   
We aimed to examine and compare the discriminatory ability of the two lung cancer 
screening tools. We did so by dividing the patients into high and low risk groups 
according to the COPD-LUCSS and the NLST criteria (Table 4) (66, 76). Cox 
proportional hazards regression was used to estimate HR for the effect of each score on 
lung cancer risk. Harrell’s C concordance statistics estimates were obtained to measure 
discrimination (97). We used the Stata command estat concordance (98). We also used 
logistic regression with lung cancer as the outcome, with 8 years of follow-up for each 
participant, to be able to estimate post hoc receiver operating curve (ROC) and intra 
model area under the curve (AUC) comparisons for the two scores (99). The Stata 
commands used were lroc and roccomp (100). This method provided a χ
2
-test for the 
difference in AUCs between the COPD‐LUCSS and the NLST. An AUC can vary 




and 100% specificity, whereas a value of 0.5 implies no discrimination. We also 
calculated the sensitivity and specificity, as well as the positive predictive values (PPV) 
and negative predictive values (NPV), for the two lung cancer screening scores. These 
terms are commonly used in diagnostic tests and screening settings. Sensitivity is the 
proportion of positives, correctly identified as that by a test. Specificity is the proportion 
of negatives, correctly identified as that (101). High sensitivity would mean that a truly 
sick person would get a positive test. This does not rule out, however, that a healthy 
person could also get a positive test. In a screening setting, one would be willing to 
accept some false positives to secure that those with a disease would have a positive 
screening test. PPV is defined as the proportion of patients with positive test results who 
are correctly diagnosed, and NPV is defined as the proportion of patients with negative 
test results who are correctly identified (101). A high NPV is essential in a screening 




Before enrolment in the GenKOLS study, oral and written information was provided, 
and written, informed consent was collected from all study participants. Data from the 
Cancer Registry of Norway and the Norwegian Cause of Death Registry were obtained 
through an application. The projects were approved by the Regional Committee for 














4. Main Results 
 
4.1. Paper I 
Non-pulmonary cancer was found in 11% of the subjects with a low level of 
emphysema, measured as %LAA, in 19% with LAA 3 10%, and in 17% of subjects 
with LAA ⩾10%, during ten years of follow-up. Corresponding numbers for lung cancer 
were 2%, 3%, and 11%, respectively. The unadjusted hazard ratios showed that older 
age, pack-years, COPD status, and amount of emphysema at baseline were significantly 
associated with both incidences of non-pulmonary cancer and lung cancer. FEV1, in 
percent predicted, was significantly associated with lung cancer in the unadjusted Cox-
regression analysis. In the adjusted Cox regression analyses, the level of emphysema 
was significantly associated with the risk of non-pulmonary cancer (HR=2.10, 95% CI 
1.14-3.87) and the risk of lung cancer (HR=3.33, 95% CI 1.04-10.61). The analyses 
were adjusted for sex, age, pack-years, age of onset of smoking, smoking status at 
inclusion, and FEV1. AWT in terms of Pi10 was not associated with non-pulmonary 
cancer or lung cancer. We found no relationship between emphysema and the location 
of cancer or the type of lung cancer.  
 
In summary, quantitatively assessed emphysema was associated with an increased risk 
of both lung cancer and non-pulmonary cancer, whereas AWT was not. 
 
 
4.2. Paper II 
For the entire sample, 8.8% of the subjects with, and 5.9% of the subjects without 
AECOPD, were diagnosed with lung cancer. In total, 58 participants (6.8%) were 
diagnosed with lung cancer during ten years of follow-up. In the adjusted Cox regression 
model with COPD patients without a history of asthma, AECOPD was significantly 
associated with lung cancer risk (HR=2.67, 95% CI 1.27-5.58), whereas not for COPD 
patients with a history of asthma. The analyses were adjusted for sex, age, pack-years, 




significant interaction between asthma and exacerbation status in the adjusted analysis 
on the entire sample.  
 
In summary, AECOPD is only significantly associated with an increased risk of lung 
cancer in COPD patients without asthma. There is a significant difference between the 
effect of AECOPD on lung cancer based on coexisting asthma.  
 
 
4.3. Paper III  
The COPD-LUCSS and the NLST selection criteria were both significantly associated 
with the risk of lung cancer in our population. The hazard ratios for the high risk versus 
the low risk groups were HR=3.0 (95% CI 1.4-6.5), and HR= 2.2 (95% CI 1.1-4.5), in 
the COPD-LUCSS, and the NLST selection criteria respectively. Harrell's C 
concordance statistic estimates were 0.63 for the COPD-LUCSS and 0.59 for the NLST 
selection criteria. The AUC values were 0.61 for the COPD-LUCSS, and 0.59 for the 
NLST selection criteria. Comparing tests found no significant difference between the 
AUC values of these criteria, p-value 0.76.  
 
In summary, even though both scores were significantly associated with increased risk 
of lung cancer, the AUC values reveal that both scores have poor discriminatory abilities 
in this cohort of COPD patients. There was no significant difference between the COPD-


















5. Methodological considerations 
 
 
Decisions concerning methodological considerations are compromises between 
available resources and the knowledge and experience that the investigator possesses. 
In this section, I will present some topics for discussion related to the study design, 
reliability and validity, and the choice of statistical methods. 
 
 
5.1. Study design 
The GenKOLS study cohort used in these studies was sampled as a case-control study 
to examine genetic factors in COPD. Therefore, the number of cancers was relatively 
small in this study compared to studies sampling target populations with cancer. Few 
cancer cases prevented us from being able to examine associations between emphysema, 
or AWT, or AECOPD and histological lung cancer types. Also, we were unable to 
examine emphysema, or AWT and different types of cancer outside the lungs. If the 
primary goal had been to examine lung cancer in COPD patients when designing the 
GenKOLS study, we would have wanted to include a control group of never-smokers in 
addition to the smoking controls. We would also have needed to estimate sample size 
based on lung cancer cases. The prospective design in this study allowed us to look at 
risk factors at baseline and outcomes further ahead in time, which is an advantage over 
a cross-sectional design, where it is impossible to say anything about cause and effect.  
 
 
5.2. Reliability and validity 
Reliability and validity are often explained through a comparison to shooting at a target. 
The goal is to hit the bull s e e on ever  attempt. High reliabilit  implies a small spread 
of bullets (Figure 3, A and D) and refers to the consistency of a measure. If similar 
results under consistent conditions are produced, the measure has high reliability. High 
reliability can be translated to low variance. The term validity comprises the closeness 




translated to low bias. As shown in Figure 3, both high reliability and validity are 
necessary to trust the results (102). 
 
 




5.2.1. Reliability in GenKOLS 
This thesis presents data on pulmonary function, smoking habits, quantitative CT 
measurements, history of asthma, exacerbations, mortality, and cancer diagnosis.  
 
Pulmonary function tests were done using standardized spirometry equipment 
(Appendix E). ATS guidelines from the time of inclusion were followed (85). These 
guidelines provide recommendations on test performance and quality control, 
contributing to high reliability.  
 
We used self-reported data on smoking habits, history of asthma, and exacerbations the 
previous year. Questionnaires are susceptible to inaccuracies due to poor recollection of 
older data or misinterpretation of the questions. Also, weak data handling afterward can 
be a problem. The wording of the questions used was based on validated studies (84), 
and precautions such as quality control and inconsistency analyses of the data entering 
were done to secure correct data handling (79).  
 
The CT images were taken according to the manufacturer s recommendations with 
standard equipment (Appendix F). Internal repeatability tests were not done to avoid 
further radiation risk. The quantitatively assessed CT scans were interpreted by a few 




randomized sub-sample of 20 subjects whose CT were interpreted by two different 
operators showed a good correlation between the quantitatively assessed measurements. 
The mean absolute difference between the two operators  %LAA-values was 0.005 
(range 0.00-0.03) (79).  
 
Data on mortality and cancer came from national registries with a high attendance rate. 
The mortality data used in this thesis was limited to all-cause mortality preventing any 
bias from the cause of death. The Cancer Registry of Norway has high reliability and 
validity (78).  
 
In summary, low reliability results in high variance and low statistical power. We were 
able to achieve high reliability for most of our variables. The inaccuracies of the 
AECOPD diagnosis might have led to lower statistical power when examining the 
relationship between AECOPD and lung cancer and will be addressed later in this 
section.  
 
5.2.2. Validity in GenKOLS 
Validity is commonly divided into internal and external validity. Internal validity 
expresses the ability of a study to draw valid conclusions regarding the study population. 
In epidemiological studies, validity includes selection bias, confounding, and 
information bias. External validity refers to how applicable the findings are to the 
general population at large. 
 
5.2.2.1. Selection bias  
Selection bias can be defined as bias resulting from methods used to select the 
participants and from factors influencing the participation in the study (103). Selection 
bias is a potential problem if the prevalence of outcomes or predictor variable varies 
amongst those who respond and those who do not.  
 
In this study, 57% of the included subjects were sampled from population-based cohorts 




The volunteers comprised 5% of the included subjects. Subjects from the patient register 
had lower lung function, were older, and had more comorbidities than cases from the 
general population (106). 4797 subjects were invited to attend the GenKOLS study, of 
which 62% attended the screening visit. 1909 fulfilled the inclusion criteria and were 
included in the study. The leading causes of non-response were unwillingness (14%) or 
feeling too ill to participate (14%), 1% lived outside Hordaland County, and 8% are 
unknown. More women than men were non-responders compared to the responders, and 
the non-responders were older than the responders (106). In addition to older age, one 
may expect more smoking in the non-responders and thus possibly a higher cancer 
incidence. A possible effect could be an underestimation of the effect of emphysema 
and AECOPD on risk of lung cancer and non-pulmonary cancer. On the other hand, we 
might expect the cancer incidence to be higher in the patients registry, compared to the 
general population, due to age (107), and therefore a corresponding overestimation of 
the effect of emphysema or AECOPD on risk of cancer.   
 
Half of the subjects underwent a CT scan (951/1909). The CT scan was an optional 
examination due to the radiation risk and was not a random selection. The examination 
was offered to the GenKOLS participants until there were approximately 500 cases and 
500 controls who had a CT scan. There were no obvious differences between the 
participants with and without a CT scan regarding age, sex, smoking habits, lung 
function, or lung cancer incidence (Table 5). Hence, we think that the fact that only half 
the GenKOLS sample underwent CT thorax examination, may not have influenced the 












Table 5. Comparison of GenKOLS subjects with and without CT 
 GenKOLS (all) GenKOLS (no CT) GenKOLS (CT)  
  No COPD COPD No COPD COPD No COPD COPD 
N 890 852 426 430 464 422 
Male (%) 50 62 47 59 54 64 
Age (Mean) 55 65 55 66 55 64 
Currently smoking (%) 41 46 41 43 42 49 
Pack-years (Median) 16 28 16 29 16 27 
FEV1 % pred (Mean) 95 51 95 49 95 53 
Lung Cancer (%) 1 7 1 7 1 7 
 
 
The mortality and cancer data came from national registries (89, 90) with no room for 
selection bias.  
 
5.2.2.2. Confounding 
A confounder is a variable (known or unknown) that influences both the predictor and 
the outcome (Figure 4, A).  
 
Figure 4. A: Confounder, B: Mediator 
P = predictor, O = outcome, C = confounder, M = mediator 
 
Known and measured confounders can be adjusted for in the statistical analyses. An 
obvious confounder when examining COPD and the risk of lung cancer is smoking, 
which causes both COPD and lung cancer. This study did not include never-smokers, 
which prevents us from generalizing the findings to a never smoking population. 
Moreover, we cannot exclude the possibility of residual confounding due to smoking. 




We had access to three different smoking variables, which were all adjusted for in Paper 
I and II. Age of onset of smoking might be important due to different susceptibility to 
epigenetic changes when starting to smoke early in life (108, 109). The acute effect of 
smoking might effect both development of emphysema and lung cancer (110), we 
therefore adjusted for smoking status at inclusion to examine the effect of emphysema, 
adjusted for the acute effect of smoking. We did, however, not know the smoking status 
at the time of the cancer diagnosis, which prevents us from fully adjust for the acute 
effect of smoking. Number of cigarettes smoked is also a known risk factor for both 
COPD (111) and lung cancer (112) and was expressed as pack-years.  
 
Lower lung function is associated with increased risk of lung cancer (37-39) and 
emphysema might lead to lower FEV1. However, lower FEV1 does not generate 
emphysema. This makes FEV1 a mediator and not a confounder (Figure 4, B). By 
adjusting for a mediator, one examines the effect on the outcome that does not go 
through the mediator. In Paper I, we adjusted for FEV1 in our analyses, knowing that 
the effect we see from emphysema on lung cancer and non-pulmonary cancer is the 
effect not mediated trough FEV1. In Paper II, we adjusted for FEV1 when examining the 
association of AECOPD and lung cancer risk. We know that lower FEV1 indicates more 
frequent exacerbations (113) and that exacerbations can lead to a quicker decline in 
FEV1 (114, 115). We adjusted for FEV1 to avoid estimating the effect of lung function 
on the risk of lung cancer.  
 
Patients with lung cancer are found to have lower socioeconomic status (SES) compared 
to subjects without lung cancer even after adjustment for smoking (116). Lower SES 
might have exposed these patients to several risk factors through work and lifestyle. One 
way to adjust for SES is through education. We had access to information on the 
participants  educational level divided into primary school, secondary school, and 
university. One could argue that the educational level should have been included when 
examining the risk of lung cancer in COPD patients. Additional adjustment for 
education did not significantly change the effect size of the predictors in the primary 




for. In conclusion, we adjusted for the most important confounders in the relationship 
between COPD and cancer. However, we cannot rule out residual confounding.  
 
5.2.2.3. Information bias 
Information bias occurs when there are measurement errors in the data collected that 
result in different information quality between compared groups (103). Information bias 
is often divided into non-differential and differential misclassification. The former refers 
to a misclassification that is probably the same across all study subjects, whereas 
differential misclassification can appear when the error is more likely in one group. In 
GenKOLS, that could, for instance, be if patients affected by COPD reported smoking 
less accurately than subjects without COPD. Questionnaires are vulnerable to 
inaccuracies. It is, however, similar to a real-life clinical setting where patients also 
might underestimate smoking consumption. A potential underestimation of tobacco 
consumption is likely the same in those with cancer compared to those without cancer, 
at least considering that the participants did not have cancer at the time of inclusion.  
 
The quantitatively assessed CT scans were interpreted by a few trained operators and 
could, to a certain degree, be operator dependent. However, operators were, blinded to 
other data, and cancer data used in this study were obtained several years after the CT 
interpretations. One could, therefore, assume that misclassifications of the 
measurements were non-differential. 
 
The participants were considered to have asthma if they gave affirmative answers to 
both: Have ou had asthma?  and if es, was this confirmed b  a doctor?  The latter 
question strengthens a true diagnosis, but still depends on the access to a doctor and that 
the doctor was right. Lung cancer was in all subjects diagnosed after baseline data 
collection, preventing recall bias. A misclassification of asthma is likely to be non-
differential by lung cancer. 
 
AECOPD was based on the questions: Have ou had treatment with antibiotics for lung 




whether pneumonia was counted as an exacerbation. Previous pneumonia predicts lung 
cancer in several studies (117) and could be a potential source of bias. 
 
We examined future diseases that the participants, and the study crew did not know 
about at the time of data sampling. We, therefore, expect potential information bias to 
be non-differential misclassification. 
 
5.2.2.4. External validity 
Results from the HCRHS are considered generalizable for the population in Hordaland 
County and the Norwegian society at large within the age-range of the study (118). The 
GenKOLS study was sampled as a case-control study, and not only sampled from 
HCRHS. In our case, however, it is more interesting to know whether the COPD cases 
are generalizable to the COPD population at large. 73% of the cases were sampled from 
a hospital registry. These patients were older, had lower lung function, and had more 
comorbidities than those recruited from other sources (107). Thus, the disease severity 
distribution is likely to be somewhat higher than in the general population (107). There 
was, however, a higher non-response rate for older people, and sicker people from the 





5.3.1. The diagnostic criterion of COPD  
At the time of study recruitment, it was common to diagnose COPD in a patient with a 
post-bronchodilator FEV1/FVC<0.70, fitting symptoms, and sufficient exposure to 
noxious particles (119). The FEV1/FVC<0.70 cut-off has correlated well with an 
increased level of respiratory symptoms (120). However, the use of the FEV1/FVC fixed 
ratio will likely cause an overdiagnosis of COPD in the elderly and underdiagnosis in 
younger adults (121). Therefore, some suggest using the fifth percentile lower limit of 
normal (LLN) of the FEV1/FVC ratio (122-125). Due to diagnostic simplicity and the 




report still recommends the fixed ratio to confirm persistent airflow limitation (1). In 
2012 new multi-ethnic reference values for spirometry for the age range 3-95 years were 
published. The authors of the global lung function 2012 equations (GLI-2012) 
recommend the use of LLN when diagnosing airway obstruction (126). Also, Norwegian 
pulmonologists recommend the use of GLI-2012 and LLN in COPD diagnosis (127). In 
our study, some COPD cases would probably be considered controls and some controls 
would be considered COPD cases with the use of LLN as opposed to a fixed ratio.  In 
Paper I, we aimed to examine the effect of emphysema and AWT on lung cancer and 
non-pulmonary cancer. Emphysema is also found in some with normal spirometry (19). 
Since we included both cases and controls with a CT scan of the lungs in the analyses, 
the definition of COPD would not influence the results. In Paper II, we included COPD 
patients based on the fixed ratio, which might have led to overdiagnosis in older 
subjects, compared to the lower limit of normal. In Paper III, we aimed to examine and 
compare a lung cancer screening score made and validated in a COPD population. We 
used the fixed ratio to define COPD just like de Torres et al. (76) to best be able to 
compare our results to theirs.  
 
5.3.2. Emphysema 
Several studies (40, 50, 51, 128, 129) found a relationship between qualitatively 
assessed emphysema and lung cancer, whereas conflicting results exist concerning 
quantitatively assessed emphysema. The qualitatively assessed method is a potential 
problem because radiographic characteristics, for instance, nodules, might affect the 
readers  interpretation of the amount of emphysema, even though they are supposedly 
unaware of the lung cancer diagnosis (50). The use of quantitative methods would 
strengthen the argument for an actual cancer risk from emphysema as compared to using 
a qualitative method.  
 
The CT scans in the GenKOLS study were acquired using a high-resolution CT 
technique, which was common during data acquisition. A standard protocol was used 
when performing the CT scans, and the measurements of emphysema have shown to be 




scans can produce overall emphysema values comparable to complete volumetric CT 
scanning (131). The X-ray attenuation cut-off was set to -950 HU for emphysema. This 
cut-off is accurate for this CT acquisition technique (86).  In conclusion, the quantitative 
CT acquisition used in this study is adequate for the aims of the study.  
 
5.3.3. Airway wall thickness 
In our study, the airway wall thickness in terms of Pi10 did not predict the incidence of 
lung cancer or non-pulmonary cancer. The lack of a relationship between AWT and lung 
cancer risk is in line with the findings of a previously published case-control study (40). 
One study was able to show a relationship between AWT and the risk of lung cancer. 
However, this association was lost when adjusting for lung function, measured as FEV1 
(55).  
 
AWT is anticipated to reflect chronic inflammation in the airways, yet we were unable 
to show an association between AWT and lung cancer risk. The changes in the airways 
that cause airflow limitation in COPD are mainly seen in the small airways, <2mm 
(132). These are difficult to measure with a CT scan, allowing assessment of the central 
airways. The findings in the central airways are, however, found to correspond to the 
distal airways (133). Airway wall thickening in COPD corresponds to chronic 
inflammation, but also structural changes including hyperplasia and hypertrophy of 
parietal glands, enlargement of goblet cells, and mucus production (134, 135). It may be 
challenging to determine whether airway wall thickness, as measured by Pi10, reflects 
active, stable, or burned out disease (136). Hence, the lack of a Pi10 lung cancer 
association in our study may indicate that Pi10 is an unspecific measure of airway 
inflammation. Consequently, we cannot rule out that there is an association between 
airway inflammation and lung cancer, but our methods have not been specific enough 








5.3.4. Asthma in patients with COPD 
Clinical studies have found the prevalence of asthma and COPD mixed phenotype in the 
COPD population to be between 20 and 40% (137, 138). In the GenKOLS population, 
we found a prevalence of COPD patients with a history of asthma close to 50%, which 
is in line with other epidemiological studies (139-142). The characteristics of COPD 
patients with asthma matched other studies in that they had a lower FEV1, higher 
exacerbation frequency, and lower tobacco consumption compared to COPD patients 
without asthma (143). One could imagine an overdiagnosis of asthma in those COPD 
patients with AECOPD due to misinterpretation of the exacerbation as an asthma attack. 
The effect on our results would depend on the link between asthma and lung cancer. If 
the lack of an association between AECOPD and lung cancer in COPD patients with 
coexisting asthma is due to a protective effect from asthma treatment, a potential 
misclassification is less likely to affect the results. If asthma itself is a protective factor, 
and several COPD patients have a wrong asthma diagnosis, this effect might be 
underestimated. A misclassification of asthma is likely to be non-differential when 
comparing those with and without cancer.  
 
5.3.5. Exacerbations  
It is common to treat moderate to severe exacerbations with either systemic steroids, 
antibiotics, or both, based on clinical presentation. In our study, we only had information 
on events that needed antibiotics. Thus, we did not know whether there were some 
events needing steroid treatment. The numbers of AECOPD were, however, similar to 
the numbers reported by the similar GeneCOPD study (55). One study by Erdal et al., 
using the EconCOPD cohort in Bergen, found that the prevalence of AECOPD using a 
symptom-based AECOPD definition was significantly higher in both a community-
based cohort and a hospital register-based cohort compared to a utilization-based 
definition (144). An underdiagnosis of AECOPD could result in less statistical power in 








5.4. Analytical considerations 
 
5.4.1. Exacerbations 
The GOLD guidelines suggest that a history of zero or one exacerbation during the 
previous 12 months represents a low future risk of exacerbations, while two or more 
represent a high risk (1). Hurst et al. (145) used the same division when they supported 
a distinct phenotype, susceptible to exacerbations. They did, however, also find an 
increased risk of exacerbation occurrence during the first year of follow-up with a 
history of at least one self-reported exacerbation during the year before inclusion (145).  
In our study, we divided AECOPD in zero exacerbations versus one or more 
exacerbations the previous year. We found the same trend in the statistical analyses 
when dividing AECOPD in zero, one, and two or more, however, not significant. The 
lack of a statistically significant association between two or more AECOPD and lung 
cancer could be due to small numbers and weak statistical power.  
 
5.4.2. Fine and Gray competing risk model 
In Paper I and Paper II, Cox proportional hazard regression was used as the primary 
statistical tool to analyze the risk (hazard) of developing lung cancer. One could argue 
that Fine and Gray competing risk regression (146), would be more appropriate because 
this model takes mortality into account as a competing risk (146). When discussing the 
prognosis of a patient, competing risk can have an impact. Taking the risk of death (or 
other competing outcomes) into account may influence whether or not to go through 
with a particular treatment. Hence, for such situations, one could argue that competing 
risk regression models are better suited for the analysis of risk factors, as opposed to 
models analyzing the single risk (hazard), as the Cox-regression model does. Still, we 
argue that using Cox regression is appropriate for the analysis of our data when 
addressing etiological questions (146). Death as a competing risk increases by 
increasing age. Therefore, in the Cox model, mortality is indirectly adjusted for through 
variables included in the analyses linked to mortality, such as age, lung function, and 




a supplementary analysis. This regression gave practically the same risk estimates as 


































6. Discussion of main results 
 
6.1. Emphysema and lung cancer 
We found a significant association between lung cancer risk and quantitatively assessed 
emphysema. Several studies have shown an increased risk of lung cancer by visually or 
qualitatively assessed emphysema (41, 50, 51), whereas not for quantitatively assessed 
emphysema (38-40). There are several feasible explanations for the discrepancy 
between our findings and those of other studies. Several of these studies were cross-
sectional or had short follow-up time (Table I), making them more vulnerable to bias 
and preventing them from saying anything about cause and effect. Common for three 
studies (38-40) using quantitative assessment were the use of an attenuation threshold 
for emphysema of -900 or -910 Hounsfield Units (HU). A threshold of -950 HU has 
shown to be appropriate for emphysema (86). One study using -950 HU as a cut-off 
found a weak association between emphysema and lung cancer. However, they 
concluded that this was not clinically relevant (148). This study adjusted for previous 
lung disease, including previous emphysema, which might explain the loss of an 
association. A recent study found that qualitative assessment was better at discovering 
mild emphysema in LDCT than quantitative assessment (149). Although emphysema in 
high resolution CT is found to be comparable to findings in LDCT, the radiation dosage, 
and the reconstruction of the pictures might affect the results (150). The lack of common 
standards for quantitative CT assessment and the lack of a suggested classification of 
%LAA stages make it difficult to compare the studies. 
 
One study showed that patients with mild COPD have the highest incidence of lung 
cancer (4), which fits with findings on decreased key inflammatory cells in mild COPD 
(151). Patients with severe COPD might be survivors without predisposing factors for 
developing lung cancer (152), or might die from competing risks such as heart disease, 
other types of cancer, or the COPD itself. Survivor bias and competing risks might both 




comparing severe emphysema to less severe emphysema. We had access to emphysema 
measurements in patients with COPD and healthy smokers and were thus able to 
compare mild emphysema to less than 3% emphysema.  
 
Two recent longitudinal studies including patients with and without COPD, confirm our 
findings in showing an increased risk of lung cancer with quantitatively assessed 
emphysema (54, 55). Carr et al. (55) found that both visually assessed emphysema and 
quantitatively assessed emphysema was associated with lung cancer. They used similar 
radiation dosage and reference values to emphysema as we did. After adjusting for FEV1 
in addition to age, ethnicity, sex, smoking status, pack-years, and years since quitting, 
the association between quantitatively assessed emphysema and lung cancer was lost. 
Some effects of emphysema on lung cancer might be mediated through FEV1. Thus, 
adjustment for FEV1 affects the association. Carr et al. had a shorter follow-up time, 
with 10% of the participants having no follow-up time at all. They state that they expect 
some of their lung cancers to be unreported (55). In several studies, the authors either 
detected lung cancers themselves during follow-up (39, 51) or were depending on 
obtaining information from the patients (50) and death certificates (55). We had 
histologically verified lung cancer diagnosis in more than 90% of the lung cancers, 
which strengthens our results. Figure 5 shows the distribution of histological lung cancer 
types found in Paper I and Paper II.  
Husebø et al. (54) examined several risk factors in COPD and lung cancer in a 
population, which included some of the same participants as in GenKOLS, sampled later 
in time. They were also able to show an increased risk of lung cancer by quantitatively 
assessed emphysema (54). There are several possible mechanisms linking emphysema 








Figure 5. Distribution of histological lung cancer types in Paper I (A) and Paper II (B) 
 
 
First, inflammation is fundamental in lung cancer pathogenesis in COPD patients (45) 
and is also present in COPD patients with emphysema (153). Pulmonary emphysema 
works to create a tumor-friendly environment (154). Murakami et al. (154) found 
overexpression of matrix metalloproteinase 9 (MMP-9), a collagenase that can facilitate 
tumor invasion and metastasis in mice with emphysematous lungs. The expression of 
MMP-9 in intratumoral stromal cells was also associated with more aggressive lung 
cancer and was mostly found in tumors from lungs with emphysema (154). One study 
from 2018 by Kerdidani et al. discovered that cytotoxic T cell responses against 
developing lung cancers are dramatically impaired by emphysema (110). Emphysema 
impacts antitumor T cell responses to a critical point at which nascent cancer cells escape 
immunity and grow unaffected (110).  The authors proposed that suppression of adaptive 
immunity against lung cancer links emphysema and COPD to lung cancer and suggested 
emphysema patients to be candidates for cancer immunotherapies (110). 
 
Second, COPD patients who have smoked have a higher risk of lung cancer than healthy 
smokers (3). Tobacco exposure induces several mechanisms, such as oxidative stress, 
chronic inflammation, and epigenetic changes. The repetitive lung injury contributes to 
a shorter lifespan in lymphocytes. It damages the DNA of lymphocytes in smokers in 
general and even more in COPD (155, 156), which weakens the immune response and 
causes an inability to remove transformed or mutated cells. Thus, increasing the 










COPD patients that are never smokers (159) and patients with alpha-1 antitrypsin 
deficiency who have not smoked (160) also have an increased risk of lung cancer. This 
implies that the effects of emphysema and COPD mentioned above might be relevant 
even if not induced by tobacco exposure. Also, not all who are exposed to tobacco 
develop COPD or lung cancer. Thus, one expects a particular susceptibility to disease 
in a subgroup of smokers. 
 
Third, the link between emphysema or COPD and lung cancer might lie in the genetics 
or epigenetics (37). CDKN2A is a shared methylation link between lung cancer and 
COPD, which encodes for tumor suppressors p16 (INK4A) and p14 (ARF) (161). This 
fits with both lung cancer and COPD being considered as diseases of aging (36, 162). 
One study found that immune genes expressed by either tumor cells or tumor-infiltrating 
immune cells in COPD patients were more methylated than those from patients without 
COPD (163). Some of the loci that regulate susceptibility for COPD in smokers might 
also determine susceptibility to lung cancer. This theory is supported by genome-wide 
association studies identifying several overlapping loci (164-166). The rs7326277TT 
genotype in VEGFR1 is a vulnerable locus in both diseases and promotes epithelial 
mesenchymal transition (EMT) and tumor growth (167). In EMT epithelial cells lose 
cell-cell adhesion. The cells produce segments of extracellular matrix and gain 
mesenchymal traits of invasion and migration (168).  Thus, COPD may epigenetically 
adjust the immune response and, therefore, increase the risk of both lung cancer and 
cancer outside the lungs. 
 
Fourth, other environmental factors such as exposure to metals and dust might cause 
both emphysema and malignancies (169). Asbestos is found to induce emphysema (170) 
and both pulmonary and non-pulmonary cancer in heavily exposed individuals (171). 
Another example is inhalable quartz, which is associated with COPD (82) and can be 
involved in lung cancer development (172). Work dust might enhance lung cancer 
development in smokers (173), whether work dust causes an additional enhancement of 




matter also increases the risk of lung cancer (174) and is associated with the prevalence 
of COPD (175). 
 
Risk factors such as indoor biomass fuel (176), and outdoor air pollution, play an 
important role in the development of COPD (177) and lung cancer, especially in low-
income countries (178). A large commission reviewing the evidence for an association 
between household air pollution and various respiratory diseases reported that 
household air pollution was associated with both COPD and respiratory tract cancer, 
including nasopharyngeal cancer and lung cancer (179). This review reported 
formaldehyde, benzene, arsenic, and nickel in the wood and coal in the household fumes, 
which are all carcinogenic to human beings (179). Biomass is also associated with 
COPD. Like tobacco, biomass from plant material generates carbon-based particles 
covered with polycyclic hydrocarbons and irritant gases such as formaldehyde (179). It 
is unclear whether COPD from biomass represents a different phenotype than tobacco-
induced COPD and, therefore, imposes a different lung cancer risk. 
 
Fifth, the airways are inhabited by bacteria, viruses, and fungi, which comprises the lung 
microbiome (180). The microbiome might change due to smoking, air pollution, or other 
irritants, causing damage to the immune system (181), possibly making the lungs more 
susceptible to cancer. To this date, the role of the lung microbiome in COPD continues 
to be uncertain. Data are inconsistent, and results across studies are difficult to reproduce 
(182). Nevertheless, the microbiome in the airways of COPD patients is different from 
healthy controls (183). We do not know whether there are microbial profiles associated 
with lung cancer. Studies on the microbiome in colon cancer have shown that bacteria 
such as Bacteroides fragilis and Fusobacterium nucleatum enhance tumorigenesis 
and regulate the tumor-immune microenvironment (184). One recent study showed an 
exclusive bacterial signature in persons with lung tumors containing TP53 mutations 
(185). One might hypothesis that the microbiome in emphysematous lungs increases 






6.2. Emphysema – and non-pulmonary cancer 
This study is the first to show that emphysema detected quantitatively on CT is 
associated with an increased risk of non-pulmonary cancer. One Danish study found an 
increased risk of smoking-related cancers in COPD patients but was unable to adjust for 
smoking (53). We had access to pack-years, age of onset of smoking, and smoking status 
at inclusion. A recent Japanese retrospective study examining airflow obstruction in 
patients with urothelial cancer found that levels of emphysema were significantly higher 
in those with airflow limitation and urothelial cancer than in those with airflow 
limitation alone (186).  
It could be that the effect of emphysema on non-pulmonary cancer in our study is mainly 
driven by smoking-related cancers such as urothelial cancers, as seen in the study by 
Naka et al. (186). We found an increased risk of non-pulmonary cancer, by amount of 
emphysema when examining non-pulmonary cancer as one group. We did, however, not 
have sufficient statistical power to examine the association of emphysema and different 
cancer types outside the lung. However, in the high emphysema group, 20% of the 
cancers were urinary tract cancers, whereas only 8% were urinary tract cancers in the 
low emphysema group (Table 2, Paper I). There might be several explanations for the 
association between emphysema and cancer outside the lungs.  
 
First, COPD and emphysema are associated with increased inflammation in the lungs 
(153). Several theories exist as to why patients suffering from COPD also have increased 
systemic inflammation. One is that the lung inflammation causes a “spillover” of 
inflammatory markers into the circulation resulting in immune reactions in the 
extrapulmonary organs (29). Inflammatory mediators such as chemokines, cytokines, 
growth factors, free radicals, and enzymes like MMPs are activated in several types of 
cancer (187). Several of these markers are also increased in patients with COPD (46, 
188) and may act to create a favorable microenvironment for the development of tumors 
(187). Accumulation of inflammatory cells like macrophages in the lung interstitium 
followed by disruption of alveolar structure and inhibition of the repair processes 
involving chemokines (CXCL-2), proteases (MMPs), and inflammatory cytokines are 




oncogenesis of urothelial cancer. MMPs induces EMT and thus regulate tumor growth 
and invasion in bladder cancer (190). In urothelial cancer, M1 macrophages are related 
to carcinogenesis by accumulating and inducing inflammation leading to EMT via 
inflammatory markers such as TNF-alfa, TGF-beta, or IL-6 (191, 192). Similar 
cytokines are found to evoke chronic inflammation in the airways (189, 193). The 
spillover of such cytokines might represent a link between COPD and cancer outside the 
lungs.  
 
Second, emphysema has been considered a marker for accelerated aging in COPD (162). 
Hence, emphysema may indicate senescence of the lungs, like muscle wasting and 
osteoporosis in COPD might indicate senescence in other organ systems. Aging is 
related to increased risk of cancer development (194). As a consequence, both 
emphysema and increased risk of cancer could be part of an accelerated aging process 
in patients with COPD.  
 
Third, smoking is also considered to alter aging, and in COPD, comorbidities have been 
associated with both the smoking itself and the accelerated aging process (195). Not all 
smokers develop COPD or smoking-related comorbidities. One clinical study showed 
significantly thicker carotid intima-media, a risk factor for cardiovascular disease, in 
smokers with airflow limitation compared to smokers without, whereas no difference 
between smokers and non-smoking controls (196). These results indicate that genetic 
and epigenetic factors might be relevant when trying to explain why some seem to be 
more susceptible to smoking-induced inflammation in the lungs and other organs. 
 
There are several chronic diseases with chronic inflammation such as diabetes, 
rheumatoid arthritis, obesity, and atherosclerosis that are found to have an increased risk 
of cancer (197-202). Several of these diseases are associated with smoking and smoking-
induced inflammation. The same mechanisms that make these smoking-induced chronic 






6.3. AECOPD in COPD patients with and without asthma and lung cancer 
We observed a significant association between AECOPD and an increased risk of lung 
cancer only in COPD patients without asthma. The association was independent of sex, 
age, BMI, lung function, pack-years, age of onset of smoking, and smoking status.  
Few other studies have examined AECOPD and lung cancer. Carr et al. found that 
incident lung cancer cases had more exacerbations at baseline than those without lung 
cancer in a cohort of patients with and without COPD (55). This association was no 
longer significant when examining the COPD cases only. Compared to Carr et al., we 
had a longer follow-up time and complete cancer data (Paper II). Husebø et al. were not 
able to show an association between AECOPD and risk of lung cancer (54). They used 
the Bergen COPD Cohort study, which partly recruited participants from the GenKOLS 
study. Their inclusion criteria required a higher smoking consumption and a smaller age 
range. Patients with previous asthma were also excluded. Husebø et al. detected 32 lung 
cancer cases and did not report the number of exacerbations. The lack of an association 
in their study could be due to small numbers and low statistical power. Our study is the 
first to explore if there is a difference in the effect of AECOPD on lung cancer based on 
coexisting asthma. Several possible mechanisms might help explain our findings. 
 
First, asthma in COPD patients was associated with a lower risk of lung cancer in a 
recent retrospective study (56). COPD with coexisting asthma might be caused by 
different mechanisms and represent a distinct phenotype with a reduced risk of lung 
cancer. There are, nonetheless, essential weaknesses in this study. They lacked 
information on lung function and tobacco exposure and were unable to adjust for these 
variables in the analyses (56). COPD patients with asthma might have smoked less and, 
therefore, have a decreased risk of lung cancer. 
 
Second, increased systemic inflammation is found in COPD patients with frequent 
exacerbations (54). AECOPD may be induced by various triggers and cause different 
inflammatory responses (203). In COPD, one often sees a neutrophilic inflammation 
driven by CD8+ T-cells, whereas eosinophilic inflammation mediated by CD4+ T-cells 




as eosinophils in our data. One might imagine a more significant contribution to the 
precancerous milieu from the neutrophilic inflammation than the eosinophilic. 
CD8+ T-cells are more dominant than CD4+ T-cells, in mild to moderate COPD 
compared to in subjects without COPD, which might be related to the susceptibility of 
viral infections (205). One study found an increased expression of programmed cell 
death (PD)-1 in CD8+ T cells and the ligand PD-L1 in patients with mild to moderate 
COPD (206). Cell cycle arrest is caused by the interaction between PD-1 and PD-L1, 
which results in T-cell anergy, meaning a reduced reaction to foreign substances by the 
body’s defense mechanisms. External administration of the influenza virus led to an 
increased tendency of dysfunctional CD8+ T cells (206). Increased expression of PD-1 
on CD8+ T-cells was also found to be higher in peripheral blood of patients with 
NSCLC,  and their interaction with PD-L1 in the tumor milieu is now an established 
target for antibody-based therapeutic interventions such as pembrolizumab in advanced 
stages of cancer (207, 208). The increased expression of PD-1 on CD8+ T-cells might 
represent a link between lung cancer and COPD, and to AECOPD induced by airway 
virus. 
 
Third, viruses and bacteria generate most AECOPD (26, 27). Several carcinogenic 
viruses and bacteria have been identified. (209, 210). Whether some virus or bacteria 
might cause cancer development in the lungs as well, remains unknown. Influenza 
increases the risk of lung cancer in some studies (211, 212). One large population-based 
cohort study from Taiwan found a decreased risk of lung cancer in COPD patients with 
influenza vaccination (212). They were able to show a dose-dependent effect and 
hypothesized less frequent exacerbations due to influenza with the vaccine, thus 
reducing persistent inflammation. They also suggested the trigger of immune response 
and antitumor defense with the vaccines (212). This study did, however, not have 
information on tobacco exposure. Studies that can adjust for smoking are needed to 
confirm their findings. Whether the mechanisms linking influenza to increased risk of 
lung cancer, also apply to other airway bacteria or viruses, such as SARS-CoV-2, 
remains unknown. Studies on different triggers of AECOPD and lung cancer might help 




with and without coexisting asthma mainly have different triggers, and therefore 
represent a different risk of lung cancer. 
 
Fourth, several studies have found a protective effect on lung cancer risk with inhaled 
corticosteroids (ICS) (54, 213-215). This could be due to reduced airway inflammation 
and decreased cell turnover, which lowers the risk of propagation of genetic errors (216). 
The protective effect of ICS on lung cancer in COPD patients might also be caused by 
reduced EMT (217). According to one report, ICS might have the ability to improve 
airway EMT in COPD (218). Characteristics of EMT are seen in the airways of smokers 
and COPD patients. Since NSCLC cells might achieve EMT phenotype (219), EMT has 
been suggested as a possible connection between cancer and COPD (220). Patients with 
coexisting asthma might have used more inhaled steroids, which might explain why 
AECOPD increases the risk of lung cancer only in COPD patients without asthma in our 
cohort.  
 
Fifth, tobacco exposure is a considerable risk factor for COPD and lung cancer. In our 
cohort, the COPD patients with asthma smoked less than those without asthma. The 
effect of smoking on chronic inflammation and enzymatic imbalance might be less 
broad in asthma patients. A recent report showed that the acute effects of cigarette smoke 
and associated infection play an essential role in driving complete EMT. The extra insult 
caused by an infection can amplify EMT, causing chronically remodeled airways, as 
seen in COPD (221).  
 
 
6.4. Lung cancer screening in a COPD population 
Even though we were able to confirm that both the COPD-LUCSS and the NLST 
selection criteria were associated with an increased risk of lung cancer, the AUC-values 
were 0.61 and 0.59, respectively, indicating poor discriminatory abilities for both scores 
(222). Almost half, 30% and 50%, of the lung cancers occurred in the low risk groups 
(Table E3, Paper III), suggesting that neither scores in their current form should be used 




Torres et al. (76) stated that the COPD-LUCSS was better than the NLST selection 
criteria at predicting lung cancer. This was examined by a visual comparison of Kaplan-
Meier curves and not tested by an objective statistical test. In our cohort, we found no 
statistically significant differences between the COPD-LUCSS and the NLST selection 
criteria (Paper III). 
 
The National Comprehensive Cancer Network recommends lung cancer screening for 
people who fulfill criteria similar to the NLST selection criteria (6). In Europe, there is 
no nationwide lung cancer screening to this date. The NELSON trial, a large Dutch-
Belgian trial including 7 900 subjects in the CT screening arm and 7 892 in the control 
arm recently reported significantly lower lung cancer mortality among participants who 
underwent CT screening compared to no screening (70). Trials are ongoing in other 
European countries (223, 224), and lung cancer screening is being discussed in most 
countries, including in Norway and other Nordic countries (225).  
 
There are still several unsolved issues concerning lung cancer screening. We do not 
know the optimal screening frequency, the necessary duration of screening, the optimal 
target population, how to define criteria for a “positive” finding, how to identify 
diagnostic follow-up protocols to minimize evaluations of false-positive findings, how 
to get sufficiently trained radiologists, a plan to reduce overdiagnosis or a plan for 
incidental findings (226). The European Respiratory Society and the European Society 
of Radiology recommend that the European countries work collectively to find the best 
solution for the implementation of lung cancer screening (226). 
 
Even though COPD is a known risk factor for lung cancer risk (36), most randomized 
control trials recruited participants based on age and smoking history alone (62, 64-68). 
All three papers in this thesis confirm an increased risk of lung cancer in subjects with 
COPD, which suggests that COPD should be considered when evaluating a target 
population for screening. A recently published study by Park et al. found that COPD in 
never-smokers was a stronger predictor of lung cancer than smokers without COPD 




in our cohort, emphysema remains a strong predictor for lung cancer. Severe COPD is 
associated with poor outcome in lung cancer (227). Thus, some patients with severe 
COPD might benefit from early detection of lung cancer. Which patients suffering from 
COPD would make the best target population, and whether patients with particular 





































Emphysema assessed quantitatively on CT was an independent risk factor for both non-
pulmonary cancer and lung cancer. Airway wall thickness in terms of Pi10 did not 




AECOPD was significantly associated with an increased risk of lung cancer only in 
COPD patients without coexisting asthma. There was a significant difference between 




The COPD-LUCSS and the NLST criteria were associated with increased risk of lung 
cancer. The AUC values showed that both scores have poor discriminatory abilities in 
our cohort. COPD-LUCSS was not significantly better than the NLST criteria in our 















8. Suggestions for future research 
 
 
The findings of this thesis give the basis for several future research questions: 
 
• CT technology keeps improving and has become a more significant part of 
diagnostics in COPD patients. The lack of standards for quantification of 
emphysema remains a problem for comparison of results in different studies. The 
lack of a reference group is also a problem for evaluation of the risk of future 
disease. Studies addressing these issues should be generated. 
• In our cohort, we had validated histological types of lung cancer, but not 
sufficient lung cancer cases to examine predictors and histological types of lung 
cancer properly. Studies on emphysema and AECOPD and types of lung cancer 
should be conducted. 
• Studies with sufficient statistical power to look into emphysema and the risk of 
different cancer types outside the lungs are needed. 
• The validity of retrospective risk factors, such as AECOPD and asthma in our 
case, is a universal problem. Other studies with validated exacerbations and 
asthma diagnosis are needed to confirm our findings. 
• Studies on types of exacerbations, including inflammatory markers, such as 
eosinophils and risk of lung cancer, are needed to understand more of the 
mechanisms linking the two diseases. 
• Studies on seasonal AECOPD, including patients from different areas of the 
world, could be beneficial to study viruses' impact on lung cancer. Virus exposure 
varies geographically and with season. 
• One study found that influenza vaccination in COPD patients was protective 
against lung cancer. This study lacked information on significant confounders. 
More studies should be conducted to confirm this finding. 
• SARS-CoV-2 is attacking the world, also generating much data on virus status. 
These data could generate baseline data for prospective cohorts to examine its 




• Patients suffering from COPD caused by other risk factors such as biomass fuel 
or outdoor air pollution might represent different phenotypes of COPD, whether 
they have a different risk of lung cancer remains unknown. Studies examining 
this link should be done. 
• It remains unknown whom to target for lung cancer screening. RCTs with COPD 
































Methods section of Paper I and Paper III 
The use of a slice thickness of 1.0 mm at 20 mm intervals when acquiring the CT 
images, was specified for the GenKOLS study. The slice thickness used was, however, 
1.25 mm at 20 mm intervals. This error was only in the description, and the correct 
slice thickness was used for all CT analyses. Thus, this had no consequences for the 
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DELTAKERINFORMASJON OG SAMTYKKESKJEMA I 
ETTERUNDERSØKELSE AV ASTMA OG ASTMALIGNENDE SYKDOMMER (KOLS) I 




Takk for din interesse. Astma og astmalignende sykdommer øker kraftig i Norge og i verden for øvrig. 
Vi prøver nå å finne årsaken til astmalignende sykdommer (emfysem, KOLS). Hvorfor får noen slike 
sykdommer av å røyke, mens andre ikke får det? Vi gjennomfører en undersøkelse ved Universitetet i 
Bergen og Haukeland sykehus i samarbeid og med finansiell støtte fra et legemiddelfirma 
(GlaxoSmithKline) som ønsker å utvikle nye legemidler mot sykdommen og nye metoder for å påvise 
sykdommen på et tidlig stadium. I alt vil ca. 5500 personer fra Bergen og omegn bli invitert til å delta. 
 
* Du deltok i vår undersøkelse omkring astma og allergi i 1998/1999. Vi vil takke deg for det. Din 
deltagelse har gitt oss verdifull kunnskap om kroniske lungesykdommer. Vi håper du igjen kan hjelpe 
oss. 
 
Vi ber deg om å fylle ut vedlagte spørreskjema og tar det med til helseundersøkelsen den … 200… 
klokken…. som vi avtalte i telefonen. Instruksjon for utfylling står øverst på spørreskjemaet. Dersom 
det nevnte tidspunktet ikke skulle passe, vennligst gi beskjed mellom klokken 08.00-11.00, telefon… 
…eller epost… … 
 
Ved undersøkelsen på sykehuset måler vi din lungefunksjon med en pustetest (spirometri). Evnen til å 
utvide luftveiene vil vi ved helseundersøkelsen teste med et legemiddel som heter salbutamol 
(Ventoline) som skal pustes inn. Det anvendes daglig av mange astmatikere i Norge. De fleste merker 
ikke noe ved å puste inn salbutamol. Noen kan få lett hjertebank og lett fingerskjelving. Mindre vanlig 
er hodepine og munn-/halsirritasjon. Vi undersøkte i 1996-99 ca. 6000 personer med denne testen og 
opplevde ingen bivirkninger. Denne for-undersøkelsen tar ca. en halv til en time. 
 
Avhengig av hva denne puste-testen viser vil du bli invitert til å delta i videre undersøkelser. Du vil da 
få ytterligere informasjon, og kan velge om du vil være med eller ikke. Hvis du vil være med, vil vi 
gjøre noen flere enkle lungefunksjonsundersøkelser. En del av dere vil også få tilbud om 
røntgenfotografering. Vi vil da se på om arvemateriale og eggehvitestoffer i blod og urin kan ha noe 
med astmalignende sykdommer (KOLS) å gjøre. Dersom du blir med i denne videre undersøkelsen, vil 
det totalt kunne ta opp til to timer (inklusive forundersøkelsen). 
 
Deltagelsen i både for-undersøkelsen og den videre undersøkelsen er frivillig. Du vil ikke bli 
behandlet annerledes av oss hvis du ikke ønsker å gjøre pusteprøven eller noen andre prøver. Du 
forplikter deg ikke til å delta i den videre undersøkelsen selv om pusteprøven skulle tilsi det. 
 
Undersøkelsen er gratis. Vi betaler parkeringsutgifter på sykehuset, og andre transportutgifter. 
Undersøkelsen er ikke ment å gi deg en helsegevinst. Du vil få skriftlig tilbakemelding om resultatet 
av lungefunksjonsmålingen, uansett resultat 







University of Bergen, Pulmonary Section, Institute of  Medicine, N-5021 Haukeland Sykehus 
Bergen <date> 
 
PARTICIPANT INFORMATION AND CONSENT FORM: 
POST-INVESTIGATION OF ASTHMA AND ASTHMA-LIKE DISEASE (COPD) IN 




Thank you for your interest. Asthma and asthma-like disease increases dramatically in Norway and in 
the world in general. We are now trying to find the cause of asthma-like diseases (emphysema, 
COPD). Why do some people develop these diseases due to smoking, while others don’t? We conduct 
a survey at University of Bergen and Haukeland University Hospital in collaboration with and with 
financial support from a pharmaceutical company (GlaxoSmithKline) who wish to develop new drugs 
against the disease and new methods for detecting the disease at an early stage. In total, approx. 5500 
people from Bergen and the surrounding communities will be invited to participate. 
 
* You participated in our survey about asthma and allergies in 1998/1999. We want to thank you for 
that. Your participation has given us valuable knowledge about chronic lung diseases. We hope you 
can help us again. 
 
We ask you to fill out the enclosed questionnaire and bring it to the medical examination on ... 200 ... 
at ....  as we agreed on the phone. Instructions for filling out the questionnaire are given at the top. If 
the agreed time is not convenient, please let us know by phone … (8:00 to 11:00 a.m.) or by email ... 
 
During the survey at the hospital we will measure your lung function using a breathing test 
(spirometry). Your ability to expand the airways will also be tested during the health survey, using a 
inhaled medicine called salbutamol (Ventoline). It is used daily by many asthmatics in Norway. Most 
people do not experience any side effects when inhaling salbutamol, but some can feel palpitations and 
light hand tremor. Less common are headaches and irritation in the mouth and throat. In 1996-99 we 
examined approx. 6000 people using this test, and experienced no side effects. This first part of the 
survey will take approx. one half to one hour. 
 
Depending on the result of breathing test, you may be invited to participate in further investigations. 
You will then get further information and can choose whether to participate or not. If you want to join, 
we will do some more simple pulmonary function tests. Some of you will also be offered 
X-ray photography. We will then look at whether genes and proteins in blood and urine may be related 
to asthma-like disease (COPD). If you join this extended part of the examination, the total could take 
up to two hours (including the first part of the examination). 
 
Participation in both the first part and the extended part of the survey is voluntary. You will not be 
treated differently by us if you do not want to take the breathing test or any other samples. You are not 
committed to participate in the extended investigation even though the breathing test should indicate 
that. 
 
The survey is free. We cover parking expenses at the hospital, and other transportation costs. 
The survey is not intended to provide you any health benefit. You will receive written feedback on the 
results of lung function tests, regardless of the outcome. 









(…fortsatt fra forrige side) 
 
Selv om du velger å delta, kan du fritt trekke deg på et hvilket som helst tidspunkt og bli fjernet fra 
videre oppfølging. Alle deltakere i denne undersøkelsen er forsikret etter de samme regler som 
gjelder for pasienter som blir undersøkt og behandlet på Haukeland sykehus. Dersom resultatene av 
undersøkelsene ved dette studiet indikerer at du skulle trenge videre undersøkelse eller behandling 
så vil dette bli dekket av vanlige offentlige forsikringssystemer i Norge. Det er GlaxoSmithKline og 
Lungeseksjonen, Universitetet i Bergen og deres samarbeidspartnere som eier studien og som kan 
bruke informasjonen for utvikling av legemidler eller annen informasjon som kan produsere 
økonomiske fordeler for institusjonene. Resultatene av studiene kan være vitenskapelige 
oppdagelser og både GlaxoSmithKline og andre forskere kan søke om patenter for slike 
oppdagelser. Vi gjør oppmerksom på at kontrollmyndighetene vil kunne ha behov for a sjekke at 
opplysninger gitt i undersøkelsen stemmer med opplysninger i din sykehusjournal for å studere 
undersøkelsens kvalitet. 
 
Undersøkelsen er godkjent av den Regionale Etisk Komite for Helseregion Vest, og Datatilsynet. 
Alle opplysninger vil bli behandlet fortrolig. De som arbeider med prosjektet har taushetsplikt både 
som forskere og helsepersonell. Vi vil gjerne beholde opplysningene med tanke på senere 
oppfølgingsundersøkelser. Skulle du ha noen spørsmål om prosjektet eller spørreskjemaet, ta gjerne 
kontakt på telefon: … … … eller … … … ... 
 
 
Med vennlig hilsen 
 
Amund Gulsvik   Per Bakke    Jan Brøgger 
Prosjektansvarlig  Overlege, professor II,  Lege, universitetsstipendiat 
Professor, overlege  Lungeavdelingen, Haukeland Universitetet i Bergen 
Universitetet i Bergen og sykehus og Universitetet i 




Jeg har lest informasjonen og er villig til å delta i forundersøkelsen og pustetesten. Jeg er klar over at 
jeg kan trekke meg når som helst uten å oppgi grunn. 
 
 





(…continued from previous page) 
 
Even if you choose to participate, you may withdraw at any time and be removed from 
further investigation. All participants in this study are insured by the same rules that 
apply to patients that are examined and treated at Haukeland Hospital. If the results of 
investigations of this study indicate that you would need further examination or treatment, 
this will be covered by regular public insurance systems in Norway. GlaxoSmithKline and 
the Pulmonary Section, University of Bergen and their partners own this study and may 
use the information for the development of drugs or other information that may produce economic 
benefits for the institutions. The results of the studies may be scientific discoveries and both 
GlaxoSmithKline and other researchers can apply for patents for such discoveries. We note that the 
supervisory board may need to check that the information given in the survey matches the information 
in your hospital records to study the quality of the survey. 
 
The survey was approved by the Regional Ethics Committee for Health Region West, and the Data 
Inspectorate. All information will be treated confidentially. Those working on the project have 
confidentiality both as researchers and health professionals. We would like to keep the information we 
have gathered to fascilitate later follow-up investigations. Should you have any questions about the 




Amund Gulsvik   Per Bakke    Jan Brøgger 
Project Manager  Consultant, Professor  MD, Research Fellow 
Professor, Consultant  Pulmonary Dept., Haukeland University of Bergen 
University of Bergen and University Hospital and 




I have read the information and I am willing to participate in the first part of this study and to take a 
breathing test. I am aware that I can withdraw at any time without giving any reason. 
 
 








* The above information, invitation and consent letter was sent to previous participants 
in SOHAS. Almost identical letters were also sent to previous participants in HCRHS 
and to participants that were selected from the HUH COPD patient registry. These 
letters differed from the above letter only by one paragraph, the second, which is 
marked with an asterix and written in italics. This paragraph describes the background 
for why the participants were invited. Below, you will find the alternative second 
paragraphs used in the letters that were sent to the participants originating from the 
HUH COPD registry and HCRHS, respectively, in Norwegian and English versions: 
 
HUH COPD registry (Norwegian) 
Vi har tatt kontakt med deg, fordi du har vært ved vår poliklinikk eller har vært innlagt 
pga. astma eller astmalignende sykdom (KOLS), ved Lungeavdelingen, Haukeland 
sykehus. 
 
HUH COPD registry (English translation) 
We have contacted you because you have been at our outpatient clinic or have been 
hospitalized due to asthma or asthma-like disease (COPD), at the pulmonary 
department at Haukeland University Hospital. 
 
HCRHS (Norwegian) 
Du deltok i vår undersøkelse omkring astma, allergi og andre lungesykdommer i 1985. 
Vi vil takke deg for det. Din deltagelse har gitt oss verdifull kunnskap om kroniske 
lungesykdommer. I 1986-87 møtte nærmere halvparten av dere til en legeundersøkelse 
ved Haukeland sykehus og i 1996-97 ble dere alle invitert til en ny helseundersøkelse 
ved Haukeland sykehus. Vi ønsker nå å gjenta denne helseundersøkelsen for å 
kartlegge din helsetilstand og hvordan din pusteevne har forandret seg. 
 
HCRHS (English translation) 
You participated in our survey about asthma, allergies and other respiratory diseases 
in 1985. We want to thank you for that. Your participation has given us valuable 




attended a medical examination at the Haukeland hospital, and in 1996-97 you were 
all invited to a new medical examination at Haukeland Hospital. We now wish to 
repeat this health survey to determine your current health condition and to see how 


















ETTERUNDERSØKELSE AV ASTMA OG ASTMALIGNENDE SYKDOMMER (KOLS) I 
BERGEN OG OMEGN I 2002-2004 
 
Hvis du ikke kan gi et helt nøyaktig svar, så fyll ut etter beste skjønn. Hvis det er spørsmål du ikke 
kan svare på, så la det stå åpent. Det utfylte skjemaet vil bli lest av en maskin. Bruk blå eller svart 
farge ved utfylling. Det er viktig at du går frem slik: 
• i de små boksene setter du kryss for det svaret som passer best for deg 
• i de store boksene skriver du tall 
 






A. Plager fra luftveiene 
1. Hoster, harker eller kremter du vanligvis om morgenen? 
2. Hoster du vanligvis ellers om dagen? 
3. Har du vanligvis oppspytt når du hoster eller harker? 
4. Hoster du daglig til sammen 3 måneder eller lenger i løpet av et år? 
5. Har du i løpet av de siste par årene i forbindelse med forkjølelse hatt hoste og/-eller oppspytt som 
har vart i mer enn 3 uker? 
6. Blir du mer tungpustet (andpusten) enn jevnaldrende når du går i motbakker? 
7. Blir du tungpustet når du går opp 2 etasjer i vanlig fart? 
8. Blir du tungpustet når du går med vanlig fart på flat mark? 
9. Er du tungpustet når du sitter i ro? 
10. Hender det at du har anfall av tung pust? 
11. Har du noen gang piping (pipelyd) i brystet? 
12. Har du noen gang i løpet av de siste 12 månedene hatt pipelyder (piping) i brystet? (Med pipelyder 
menes høye eller dype lyder som også kan være svake) 
Hvis ja: 
13. Har du vært tungpustet i forbindelse med at du hadde pipelyder i brystet? 
14. Har du hatt slike pipelyder når du ikke har vært forkjølet? 
 
B. Allergier 
1. Har du noen gang hatt høysnue?  
2. Hvis ja: 
Har du de siste 12 måneder hatt høysnue? 
3. Har du noen gang hatt høysnue og/eller pollenallergi?  
 
C. Astma eller astmaliknende sykdom (KOLS) i familien 
1. Har følgende av dine biologiske slektninger hatt astma eller astmaliknende sykdommer (KOLS, 
emfysem)? 
a) Mor:  
b) Far:     
        (Fortsetter…) 
 










POST-INVESTIGATION OF ASTHMA OG ASTHMA-LIKE DISEASE (COPD) IN 
BERGEN AND SURROUNDING COMMUNITIES IN 2002-2004 
 
If you cannot give an exact answer, please fill out at your best discretion. If there are questions you 
cannot answer, leave it blank. The completed form will be read by a machine. Use blue or black color 
when filling it out. It is important that you proceed as follows: 
• in the small boxes, please tick the answer that best suits you 
• in the large boxes, please type numbers 
 







A. Symptoms from the respiratory tract 
1. Do you usually cough, hark or hawk in the morning? 
2. Do you usually cough during the rest of the day? 
3. Do you usually have phlegm when you cough or hark? 
4. Do you cough daily for 3 or more months in one year? 
5. Have you, in the last couple of years, had cough and / or phlegm for more than 3 weeks in 
conjunction with a cold? 
6. Do you experience more shortness of breath than your peers when walking uphill? 
7. Do you get breathless when ascending two flights of stairs at normal speed? 
8. Do you get breathless when walking at normal speed on level ground? 
9. Do you get breathless when sitting quietly? 
10. Do you have attacks of breathlessness? 
11. Have you ever experienced wheezing in your chest? 
12. Have you experienced wheezing in your chest in the last 12 months? (Wheezing is high- or low- 
pitched sounds that can also be weak.) 
If yes: 
13. Do you get breathless in conjunction with the wheezing? 
14. Have you experienced wheezing when you were not having a cold? 
 
B. Allergies 
1. Have you ever had hay fever?  
2. If yes: 
Have you had hay fever in the last 12 months? 
3. Have you ever had hay fever and / or pollen allergy?  
 
C. Asthma or astma-like disease (COPD) in the family 
1. Have any of your biological relatives had asthma or asthma-like disease? (COPD, 
emphysema)? 
a) Mother: 
b) Father:  
 
(Continues…)  




(…fortsatt fra forrige side) 
 
D. Lunge- og hjertesykdommer 
Er du noen gang blitt behandlet av lege eller har du vært innlagt i sykehus for en av de sykdommene 
som er nevnt nedenfor? 
1. Astma?  
Hvis ja: 
Hvor gammel var du da sykdommen begynte? 
Hvis du ikke lenger har astma, hvor gammel var du da den da seg? 
2. Bronkitt?  
Hvis ja: 
Hvor gammel var du da sykdommen begynte? 
Hvis du ikke lenger har bronkitt, hvor gammel var du da den ga seg? 
3. Emfysem?  
Hvis ja: 
Hvor gammel var du da sykdommen begynte? 
4. Kronisk obstruktiv lungesykdom (KOLS)?  
Hvis ja: 
Hvor gammel var du da sykdommen begynte? 
5. Hjerteinfarkt?  
6. Angina pectoris?  
 
E. Røykevaner 
1. Røyker du daglig for tiden? 
Hvis ja: 
2. Røyker du sigaretter daglig (håndrullede eller fabrikkfremstilte)? 
Hvis nei: 
3. Har du røykt sigaretter daglig tidligere? 
Hvis ja: 
4. Hvor lenge er det siden du sluttet? 
Mindre enn tre måneder 
Tre måneder til ett år 
Ett år til fem år 
Mere enn fem år 
 
Følgende spørsmål besvares kun hvis du røyker nå eller har røykt tidligere: 
6. Hvor mange år har du røykt daglig? ___ 
7. Hvor mange sigaretter røyker du eller røykte du daglig? (oppgi antall pr dag, både 
håndrullede og fabrikkfremstilte) _____ 
8. Hvis du røyker, har noen lege anbefalt deg å slutte å røyke? 
9. Har du prøvd nikotinplaster, nikotintyggegummi eller nikotininhalator for å slutte å røyke? 
10. Har du prøvd røykesluttpillen Zyban for å slutte å røyke? 
11. Har du deltatt på røykeavvenningsmøter eller kurs? 
 
F. Din utdannelse og arbeid 
1. Vennligst kryss av for det utdanningsalternativ som passer best for deg: 
Tidligere folkeskole eller nåværende 9-årig grunnskole 
Framhaldsskole, folkehøyskole og andre tilsvarende skoler 
Middelskole, realskole, gymnas, videregående skole, yrkesskole eller annen fagskole 
Høyskole, universitet 
 
2. Har du noen gang hatt en arbeidsplass med mye støv eller gasser i luften?  
 
(Fortsetter…) 





D. Lung and heart disease 
Have you ever been treated by a physician or admitted to a hospital because of any of the below 
mentioned diseases? 
1. Asthma?  
If yes: 
How old were you when the disease started? 
If you no longer have asthma, how old were you when the symptoms stopped? 
2. Bronchitis?  
If yes: 
How old were you when the disease started? 
If you no longer have bronchitis, how old were you when the symptoms stopped? 
3. Emphysema?  
If yes: 
How old were you when the disease started? 
4. Chronic obstructive lung disease (COPD)?  
If yes: 
How old were you when the disease started? 
5. Heart attack?  
6. Angina pectoris?  
 
E. Smoking habits 
1. Are you currently a daily smoker? 
If yes: 
2. Do you smoke cigarettes daily (hand-rolled eller prefabricated)? 
If no: 
3. Have you previously been a daily smoker? 
If yes: 
4. How long is it since you quit? 
Less than 3 months 
3 months to a year 
1 to 5 years 
More than 5 years 
 
The following questions should only be answered if you are a current or previous smoker: 
6. For how many years have you been a daily smoker? ___ 
7. How many cigarettes do you or did you smoke per day (both hand-rolled and 
prefabricated)? _____ 
8. If you are a current smoker, has a physician ever advised you to quit smoking? 
9. Have you tried nicotine patches, gum or inhaler in order to quit smoking? 
10. Have you tried to quit smoking using the quitting-pill Zyban? 
11. Have you participated on any smoke quitting sessions or meetings? 
 
F. Your education and work 
1. Please tick the option that best describes your educational level: 
Former primary school or present 9-year primary school 
Continuation school, 1-year people’s college and similar schools 
Lower/upper secondary school or technical school 
College or university 
 






(…fortsatt fra forrige side) 
 
G. Mors og fars utdannelse 
1. Vennligst kryss av for det utdanningsalternativ som passer best for din mor og far: 
FAR MOR 
Tidligere folkeskole eller nåværende 9-årig grunnskole 
Framhaldsskole, folkehøyskole og andre tilsvarende skoler 




H. BRUK AV HELSETJENESTER OG TRYGD 
1. Har du astma, bronkitt emfysem eller kronisk obstruktiv lungesykdom?  
Hvis nei, hopp til neste seksjon. 
Hvis ja: 
2. Bruker du astmamedisiner nå? (inkludert spray, pulverinhalasjoner, tabletter)  
3. Går du til kontroll hos lege for den sykdommen?  
Hvis ja: 
4. Går du til: 
Allmenpraktiker, kommunelege 
Bedriftslege 
Lungelege eller spesialist i lungesykdommer 
Annen lege 
Når var du til kontroll sist? for __ måneder siden 
Hvor mange ganger har du vært innlagt på sykehus for den sykdommen siste 12 måneder? 
__ ganger 
Er du i lønnet arbeid?  
Hvis ja: 
Hvor lenge har du vært sykemeldt tilsammen pga. den sykdommen siste 12 måneder 
Ingen dager 
0-7 dager (En uke eller mindre) 
8-30 dager (Mere enn en uke, men ikke mere enn en måned) 
31-90 dager (Mere enn en måned, men ikke mere enn tre måneder) 
Over 90 dager (Mere enn tre måneder) 
Er du uføretrygdet pga. overnevnte sykdommer? 
 
I. Høyde og vekt 
1. Hvor høy er du (cm)? 






Takk for at du har tatt deg tid til å fylle ut skjemaet! Husk å ta det med til avtalt 






(…continued from previous page) 
 
G. Parents’ education 
1. Please tick the option that best describes your parents’ educational level: 
FATHER MOTHER 
Former primary school or present 9-year primary school 
Continuation school, 1-year people’s college and similar schools 
Lower/upper secondary school or technical school 
College or university 
Don’t know 
 
H. USE OF HEALTH SERVICES AND SOCIAL SECURITY 
1. Do you have asthma, bronchitis, emphysema or chronic obstructive pulmonary disease? 
If no, skip to the next section. 
If yes: 
2. Are you currently using asthma medication? (Included spray, dry powder inhalers and pills)  
3. Are you seeing a physician for the above mentioned diseases? 
If yes: 





When did you last see your physician?  __ months ago 
How many times have you been admitted to a hospital for the above mentioned diseases in the 
last 12 months? __ times 
Are you employed?  
If yes: 
What is the total number of days that you have been on sick-leave due to the above 
mentioned diseases in the last 12 months? 
No days 
0-7 days (One week or less) 
8-30 days (More than a week, but less than a month) 
31-90 days (More than a month, but less than 3 months) 
More than 90 days (More than 3 months) 
Are you receiving disability pension due to the above mentioned diseases? 
 
I. Height and weight 
1. How tall are you (cm)? 






Thank you for taking the time to fill out this form! Please remember to bring the form when you 




















Forespørsel om deltagelse i en undersøkelse på arvemateriale hos pasienter med astmalignende sykdom 
(kronisk obstruktiv lungesykdom, KOLS) og kontrollpersoner 
(PROTOKOLL GenKOLS) 
 
Du er blitt forespurt om å delta i en studie som gjøres av Universitetet i Bergen i samarbeid med og med 
finansiell støtte av legemiddelfirmaet GlaxoSmithKline (GSK). Før du bestemmer deg for å delta, bør du sette 
deg inn i hva studien går ut på. Denne informasjonen forklarer studien slik at du får grunnlag til å vurdere om du 




Hovedhensikten med studien er å undersøke arvematerialer (DNA og RNA som inneholder gener) og 
proteiner (lages med informasjon fra gener) som har noe med KOLS å gjøre. Du er spurt om du vil være med 
i denne undersøkelsen enten fordi du har astmaliknende sykdom (KOLS), eller fordi du er røyker eller er 
tidligere røyker men ikke lider av astmaliknende sykdom (KOLS). 
 
Ved å sammenligne ditt arvematerialer og visse proteiner som lages i deg, med arvematerialer og proteiner 
som lages i personer som ikke har KOLS, kan vi få nyttig informasjon om hva gener har å si for denne 
sykdommen. Universitetet i Bergen og GSK har satt i gang denne studien, og de betaler kostnadene for 
studien. Til denne studien trenger vi resultater fra omlag 2000 deltagere. Studien gjøres i Norge av professor 
overlege Amund Gulsvik, som er spesialist på lungesykdommer, og hans medarbeidere. 
 
Hva som forventes av deg dersom du bestemmer deg for å delta 
Før studien kan starte må du lese denne informasjonen og du vil også få anledning til å stille spørsmål om det er 
noe du lurer på. Det blir også spurt etter din families sykehistorie og etnisk tilhørighet. 
Du må gi skriftlig samtykke for å få delta. 
 
Hva blir jeg bedt om å gjøre hvis jeg samtykker til å delta? 
Du vil bli bedt om å gi informasjon om din sykdom og om din generelle helsetilstand og om evt medisiner du 
tar. Du har allerede fått gjennomført en pusteprøve (spirometri) med astmamedisinen Ventoline og lytting på 
lungene med stetoskop. Den andre testen (Gas Transfer) måler dine lungers kapasitet til å utveksle gasser, 
med en ufarlig testgass, som er hovedfunksjonen til lungene. 
 
Dersom du ikke har hatt utført en CT undersøkelse (en type røntgenundersøkelse av lungene) i løpet av de siste 2 
år er det mulig at dette gjøres i forbindelse med denne studien. Testen krever at du må puste helt ut og 
puste dypt inn – for så å holde pusten opp til 10 sekunder – før du puster godt ut igjen. 
Det vil bli tatt blodprøve av deg. Denne vil bli brukt for undersøkelse av ditt arvemateriale (DNA) og andre 
blodprodukter, for eksempel proteiner. Det vil bli tatt ca. 60 ml (tilsvarer 5 ss) blod. 
 
Kriterier for deltagelse 
Du må være 40 år eller eldre, og enten ha diagnosen KOLS og en sykehistorie som passer med studieplanen, 
eller være røyker eller tidligere røyker og fri for KOLS og ellers passe med studieplanen. 
 
Mulig risiko ved å delta 
Undersøkelsene som inngår i denne studien gjøres slik de blir gjort vanligvis på sykehuset. Noen synes det er 
















Participant information/consent form II 
 
Request for participation in a survey of genes in patients with asthma-like disease 
(chronic obstructive pulmonary disease, COPD) and control subjects  
(PROTOCOL GenKOLS) 
 
You have been asked to participate in a study carried out by the University of Bergen in cooperation with and 
with financial support from the pharmaceutical company GlaxoSmithKline (GSK). Before you decide to 
participate, you should familiarize yourself with what the study entails. This information explains the study to 
give you a basis to decide whether or not to participate. The study is recommended by the Regional Ethical 
Committee for Medical Research, Health Region West (REK III). 
 
The purpose 
The main purpose of this study is to investigate the genetic material (DNA and RNA that contains genes) and 
proteins (made with information from genes) that are related to COPD. You have been asked to participate 
in this study either because you have asthma-like disease (COPD), or because you are a smoker or 
former smoker but not suffering from asthma-like disease (COPD). 
 
By comparing your genetic material and certain proteins that are produced within you, with genetic material and 
proteins from people with COPD, we can get useful information about the influence of genes on this 
disease. The University of Bergen and GSK has initiated this study, and they finance the costs of 
this study. For this study we need results from approx. 2000 participants. The study is carried out in Norway by 
professor and pulmonary consultant Amund Gulsvik and his co-workers. 
 
What is expected of you if you decide to participate 
Before the study can begin, you must read this information, and you will also have the opportunity to ask 
questions. You will also be asked about your family's medical history and ethnicity. 
You must give written consent to participate. 
 
What will I be asked to do if I agree to participate? 
You will be asked to provide information about your diseases and your general health, and about any medication 
you might be taking. You have already completed a breathing test (spirometry) with the asthma medication 
Ventoline, and we have listened to your lungs with a stethoscope. The second test (Gas Transfer) measures the 
capacity of your lungs to exchange gases using a harmless test gas, and this is the main function of the lungs. 
 
If you have not undergone a CT examination (a type of X-ray examination of the lungs) within the last 2 years, it 
is possible that this will be done in connection with this study. The test requires you to exhale completely and 
inhale deeply - and then hold your breath for up to 10 seconds - before you can exhale. 
Blood samples will be taken. These will be used for analyses of your genetic material (DNA) and other 
blood components such as proteins. Approx. 60 ml (equivalent to 5 tablespoons) of blood will be drawn. 
 
Criteria for participation 
You must be 40 years or older. You must either have diagnosed COPD and a medical history that fits the study 
protocol, or be a current or former smoker without COPD and otherwise fit the study protocol. 
 
Possible risks of participating 
The tests and examinations included in this study are performed the way they are usually done at the hospital. 







(…fortsatt fra forrige side) 
 
Hvis en CT undersøkelse blir utført vil du få en mindre strålingsdose, som når man flyr fra Norge til USA. Jo 
mere stråling du får i løpet av ditt liv, jo større er risikoen for kreft og svulster eller for å påføre forandringer 
til dine gener. Hvis du har mistanke om at du er gravid skal du unngå å ta denne testen. 
 
Mulige fordeler ved å delta 
Du vil ikke ha noen direkte nytte av å delta i en slik studie. Resultatene fra denne studien kan bli nyttig for 
pasienter med KOLS i fremtiden. Vi kan lære mer om sykdommen KOLS og vi kan få informasjon som kan 
gjøre det mulig å utvikle bedre medisin for pasienter med KOLS. 
Resultatene vil ikke være klare før om flere år. Informasjon fra lungefunksjonstesten vil bli gitt deg skriftlig av 
en lege. Du vil også bli informert om resultatene av røntgenbildet av lungene, hvis dette blir tatt. 
 
Personlige opplysninger og konfidensialitet 
Alle person-opplysninger behandles konfidensielt og i henhold til kravene i de nye forskriftene til 
Personregisterloven. Blodprøven og de medisinske opplysningene identifiseres med et studieidentitetsnummer, 
ikke navnet eller personnummeret ditt. Det er kun prosjektansvarlig lege og de i hans stab 
som jobber med studien som har både navnet ditt og studie-identitetsnummeret du er tildelt. Dette innebærer 
at andre ikke vil kunne spore innsamlet genetisk informasjon som er fremkommet om deg, tilbake til deg. Det 
tilrettelegges for at dette opprettholdes gjennom hele studien. I tillegg vil din deltakelse i denne studien ikke 
dokumenteres i din vanlige sykehusjournal. 
 
Vi vil gjerne ha muligheten til å se hvordan det går med deg i fremtiden. Men samtidig ønsker vi at du skal 
være anonym, spesielt med tanke på genene. Derfor gjør vi sånn som dette: Vi sender de opplysningene som 
vi får av deg nå i dag, til en utenforstående offentlig institusjon som ikke har noe med studien å gjøre. Om 
noen år håper vi å kontakte deg på nytt, blant annet for å måle lungefunksjonen din. Så vil vi sende disse dataene 
til denne utenforstående offentlige institusjonen. De sender dataene i anonymisert form tilbake til oss, slik at de 
ikke kan spores tilbake til deg. Slik kan vi se på genenes betydning for lungehelse over tid, men samtidig la deg 
være anonym. Den utenforstående offentlige institusjonen er Kreftregisteret. 
 
Innsyn i din journal 
Om du sier deg villig til å være med i denne studien, sier du deg også villig til å gi visse andre enn 
prosjektansvarlig lege og hans medarbeidere tilgang til din sykehusjournal, hvis du har en slik journal på 
sykehuset. De andre instanser som kan ha behov for tilgang på din journal er representanter fra offentlige 
kontrollmyndigheter og representanter fra legemiddelfirmaet, GlaxoSmithKline. Disse trenger å ha tilgang til 
din journal for å sjekke at opplysninger gitt i studien stemmer med opplysninger i din journal, for å kontrollere 
studiens kvalitet. Innsynet gjelder for den begrensede tidsperiode studien går over og gjelder for studie-relatert 
informasjon. Den lege du vanligvis går til (fastlegen) vil få opplysninger om din deltagelse i studien dersom du 
ikke har noe imot det. 
 
Databearbeidelse 
I forbindelse med denne utprøvningen har vi fått tillatelse av Datatilsynet til å opprette et dataregister for å bli i 
stand til å behandle resultatene på en rask og effektiv måte. Bearbeidelse av dataene vil foregå under kontroll av 
Universitetet i Bergen og GSK og vil bli overført til et annet land. Universitetet i Bergen og GSK vil ikke gi 
tilbakemelding til den enkelte deltager, lege, forsikringsselskap eller arbeidsgiver om resultater fra denne type 
undersøkelse unntatt slike individuelle resultater som er nevnt ovenfor. Resultatene vil bli analysert og brukt av 
forskere ved Universitetet i Bergen og GSK og samarbeidende institusjoner. Ingen, inkludert deg selv, har krav 
på resultater fra de genetiske prøvene. Resultatene vil foreligge som forskningsrapport uten at noe kan knyttes til 
en deltager. Det er Universitetet i Bergen og GSK og de som Universitetet i Bergen og GSK samarbeider med, 
som eier resultatene fra studien, og som har rett til å bruke informasjonen til sin videre utvikling av medisiner 
eller annen informasjon som kan gi økonomiske fordeler for institusjonene. Resultatene fra studien kan være 
vitenskapelige oppfinnelser, og både Universitetet i Bergen, GSK og andre forskere kan komme til å søke om 
patent for slike oppfinnelser. 
 
Hva vil skje med blodprøven som er tatt? 
Blodcellene i blodprøven din inneholder ditt arvemateriale. De vil bli dyrket slik at de gir opphav til mange 
nye, men identisk like blodceller. På denne måten får forskerne flere blodceller de kan skille ut arvemateriale 
fra. Dermed får de mer av ditt arvemateriale som kan analyseres ved det laboratoriet som får tilgang til prøven 
eller blodcellene. Prøven/blodcellene vil bli analysert i utlandet og i Norge. Slik gir din blodprøve opphav til 




(…continued from previous page) 
 
If a CT examination is performed, you will get a small dose of radiation, comparable to a flight from Norway to 
the United States. The more radiation you receive during your life, the greater the risk of cancer and tumors or to 
cause changes to your genes. If you suspect that you are pregnant you should avoid taking this test. 
 
Possible benefits of participating 
You will not have any direct benefit from participating in such a study. The results from this study may become 
useful for patients with COPD in the future. We can learn more about COPD and we may get information that 
can make it possible to develop better medication for patients with COPD. 
The results will not be ready for several years. Information from the lung function tests will be given to you in 
writing by a doctor. You will also be informed of the results of the lung X-ray, if it is taken. 
 
Personal information and confidentiality 
All personal information is treated confidentially and in accordance with the requirements of the new regulations 
of Personregisterloven (Personal Registry Act). Blood samples and medical information is identified by a study 
ID number, and not by your name or social security number. Only the project manager and some of his study 
staff have access to both your name and study ID number. This means that others will not be able to link the 
collected genetic information back to you. This policy will be maintained throughout the study. In addition, your 
participation in this study will not be documented in the normal hospital records. 
 
We'd love to have the opportunity to check up on you in the future. However, we want you to remain 
anonymous, especially in terms of genes. Therefore, we do like this: We send the information 
we get from you today to an independent public institution. In a few years we will hopefully contact you again, 
in order to measure your lung function. Then we will send this data to the independent public institution. They 
will send the data in an anonymous form back to us, so that they cannot be traced back to you. This way we can 
study the importance of genes on lung health over time while you remain anonymous. The outside public 
institution in question is the Kreftregisteret (Cancer Registry). 
 
Access to your medical records 
If you agree to participate in this study, you also agree to provide access to your hospital records, if you have 
such records, to certain others than the project manager and his staff. The other agencies that may need access to 
your medical records are representatives from public control authorities and representatives from the 
pharmaceutical company, GlaxoSmithKline. They need access to your records to control that the study 
information is coherent with the information in your medical records. This access is time-limited for the duration 
of the study, and concerns only study-related information. The physician you usually see (GP) will get 
information about your participation in the study if you do not have any objections. 
 
Data Processing 
In connection with this study, we have been given permission by the Data Inspectorate to create a data registry to 
be able to process results in a rapid and efficient manner. The processing of the data will be under the control of 
the University of Bergen and GSK, and the data will be transferred to another country. The University of Bergen 
and GSK will not give feedback to each participant, physician, insurance company or employer about the results 
from this type of investigation other than such individual results mentioned above. The results will be analyzed 
and used by researchers at the University of Bergen and GSK and collaborating institutions. No one, including 
yourself, are entitled to the results of genetic tests. The results will be published as a research report without any 
information that can be related to any single participant. It is the University of Bergen and GSK and their 
collaborators who owns the results from this study, and who has the right to use this information for 
development of medicines or other information that can provide economic benefits for the institutions. The study 
may result in a scientific inventions, and both the University of Bergen, GSK and other researchers may apply 
for a patent for such inventions. 
 
What will happen to the blood sample that was taken? 
The blood cells in your blood sample contain your genetic material. They will be cultivated so that they give rise 
to many new but identical blood cells. This method gives researchers more blood cells that they can separate 
genes from. As a result, an increased amount of your genetic material will be available for analysis by the 
laboratory. The sample / blood cells will be analyzed abroad and in Norway. In this way your blood sample gives 
rise to cells that can be used in research on COPD in an unlimited period. 





(…fortsatt fra forrige side) 
 
Deltar jeg frivillig? Kan jeg trekke meg? 
Deltakelse er helt frivillig. Du kan velge ikke å delta, eller du kan velge å delta, og senere, uten å angi årsak, 
forandre mening og trekke deg. Dersom du velger å trekke deg fra studien før den slutter, vil den prøven av 
genene som ble tatt av deg og de celler som er dyrket frem fra den, ødelegges. 
 
Forsikring 
Alle deltakere i undersøkelsen er forsikret etter de samme regler som gjelder for pasienter som blir undersøkt 
og behandlet på Haukeland sykehus. Erstatning for evt. påførte skader som følge av studien vil behandles etter 
regler for Norsk pasienterstatning. Hvis resultatene av disse undersøkelsene tilsier at du bør gå til legekontroll 
eller få behandling, vil disse kostnadene bli dekket av det offentlige helsevesenet. 
 
Deltagelse i studien 
Du står helt fritt til å bestemme om du vil delta i denne studien. Hvis du velger å delta, kan du trekke deg når 
som helst uten å angi noen årsak. Dette vil ikke ha noen betydning for den generelle behandling du gis eller for 
ditt forhold til sykehuset. Dersom du er villig til å delta vil du bli undersøkt /stilt spørsmål som beskrevet 
tidligere i denne informasjonen, for å finne ut om du passer til å være med i studien. Studien kan stoppes, og da 
vil du bli informert om dette. 
Det vil ikke medføre ekstra kostnader for deg ved å delta i dette prosjektet. Du vil ikke bli betalt for 
deltagelse, men du vil få refundert dine transportutgifter. 
Hvis du i løpet av undersøkelsen har spørsmål angående denne studien og din rettighet som deltager, kan du 
kontakte en av de nedenfor nevnte legene: 
 
Amund Gulsvik    Per Bakke    Jan Brøgger 
Telefon: 55973242  Telefon: 5597....   Telefon: 55974066 
Mobiltelefon: 92867303 
Prosjektansvarlig   Overlege, professor II,  Lege, universitetsstipendiat 
Professor, overlege  Lungeavdelingen, Haukeland Universitetet i Bergen 
Universitetet i Bergen og  sykehus og Universitetet i 
Lungeavdelingen, Haukeland Bergen 
sykehus 
 
Samtykke til å delta i studien 
Jeg har mottatt og lest denne informasjonen. Jeg har hatt anledning til å stille spørsmål om studien og hva den 
innebærer. Jeg er klar over at jeg kan trekke meg når som helst uten å oppgi grunn. 
Jeg samtykker med dette til å delta i studien og å bli registrert i en forskningsdatabase i forbindelse med 
gjennomføring av studien. Jeg samtykker i at jeg som deltager ikke får noen økonomisk kompensasjon og at 
patent på evt resultater kan søkes av Universitetet i Bergen, GSK og andre forskere. 
 
 
............................................................ ……………………………………… ………………….. 




Undertegnede bekrefter med dette at studiedeltageren har fått muntlig informasjon, blitt gitt anledning til å 
lese informasjonen, stille spørsmål angående denne studien, og har fatt tid til å vurdere sin deltagelse før 
han/hun har undertegnet og datert dette samtykke-skjemaet. 
 
Lege evt. personell som har gitt 
informasjon og tatt imot samtykke: 
 
……………………………………… ………………………………………. …………………. 
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Do I participate voluntarily? Can I withdraw? 
Participation is completely voluntary. You can choose not to participate, or you may choose to participate, and 
then later change your mind and withdraw, without specifying why. If you choose to withdraw from the study 
before it ends, the samples that were taken from you, including any grown cell cultures, will be destroyed. 
 
Insurance 
All participants in this study are insured by the same rules that apply to patients who are examined 
and treated at Haukeland University Hospital. Compensation for any harm as a result of the study will be treated 
by the rules for the Norwegian patient compensation. If the results of these investigations suggest that you 
should see a physician or receive treatment, these costs will be covered by public health care system. 
 
Participation in the study 
You are free to decide whether to participate in this study or not. If you choose to participate, you can withdraw 
at any time without giving any reason. This will have no impact on your general treatment or for your 
relationship to the hospital. If you are willing to participate, you will be examined / questioned as described 
previously in this information, to determine that you fulfill the criteria to participate in the study. The study can 
be terminated, and if so you will be informed. 
Participating in this project will not incur any additional cost for you. You will not be paid for participation, but 
you will be reimbursed your travel expenses. 
If you in the course of this investigation have any questions about this study or your rights as a participant, you 
can contact any of the below-mentioned study physicians: 
 
Amund Gulsvik    Per Bakke    Jan Brøgger 
Telephone: 55973242  Telephone: 5597....  Telephone: 55974066 
         Mobile: 92867303 
Project Manager   Consultant, Professor  Physician, Research fellow 
Professor, Consultant  Pulmonary Dept, Haukeland  University of Bergen 
University of Bergen and  University Hospital and 
Pulmonary Dept, Haukeland University of Bergen 
University Hospital  
Consent to participate in the study 
I have received and read this information. I have had the opportunity to ask questions about the study and what it 
entails. I am aware that I can withdraw at any time without giving any reason. 
I hereby agree to participate in this study and to be registered in a research database as part of the study. I agree 
that I as a participant will not receive any financial compensation and that patents on possibly results can be 
sought by the University of Bergen, GSK and other researchers. 
 
 
.................................................. ........ .. ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .  .. ... ... ... ... ... 




The signatory confirms that the study participant has received verbal information and has been given the 
opportunity to read the information, ask questions about this study and has had extensive time to consider their 
participation before he / she has signed and dated this consent form. 
 
Study physician or other study personnel that has given 
information and received the consent: 
 
... ... ... ... ... ... ... ... ... ... ... ... ... ... ... . .. ... ... ... ... ... ... ... ... ... ... ... ... ... .... ... ...   ... ... ... ... .... 










Case-control questionnaire: English translations / Norwegian versions of selected 






- Have you ever smoked cigarettes? (‘No’ means less than 1 cigarette a day for 1 year) 
(Yes, No, Don’t know) 
If yes:  
- Do you smoke cigarettes now (as of 1 month ago)? (Yes, No, Don’t know) 
- At what age did you first start smoking regularly? (Age) 
- If you have stopped smoking cigarettes completely, how old were you when 
you stopped? (Age) 
- How many cigarettes do you now smoke per day? (Number) 
- Historically, what is the average number of cigarettes that you smoked per 
day? (Number) 
- Har du noensinne røykt sigaretter? (”Nei” betyr mindre enn 1 sigarett om dagen i 1 
år) 
 (Ja, Nei, Vet ikke) 
Hvis ja: 
 - Røyker du sigaretter nå (dvs for 1 måned siden)? (Ja, Nei, Vet ikke) 
 - Hvor gammel var du da du først begynte å røyke regelmessig? (Alder) 
 - Hvis du har sluttet helt å røyke sigaretter, hvor gammel var du da du sluttet? 
(Alder) 
 - Hvor mange sigaretter røyker du nå per dag? (Antall) 




- Have you had any of the following: 
- Asthma? (Yes, No, Don’t know) 
 If yes: 
- Was this confirmed by a doctor? (Yes, No, Don’t know) 
- Har du hatt noen av de følgende: 
- Astma? (Ja, Nei, Vet ikke) 




- Ble dette bekreftet av lege? (Ja, Nei, Vet ikke) 
 
Exacerbations 
- Have you had treatment with antibiotics for a lung disease during the last 12 months? 
(Yes, No, Don’t know) 
 If yes: 
- How many times? 
- Har du få tt behandling med antibiotika for en lungesykdom i løpet av de siste 12 
månedene? (Ja, Nei, Vet ikke) 
Hvis JA: 















Technical Specifications ... Vitalograph® GoldStandard 
+   
Parameters measured  configurable by operator  
Measuring principle   dry wedge type bellows 
Measuring accuracy      better than +3%/50mL (ATS 1994) 
Linearity   litre-by-litre system 
Size   460 x 465 x 290mm 
Weight 9.1 Kg  
Back pressure   <2.5cmH2O/L/s (Complies to ATS 1994) 
Volume measurement   direct 
Maximum recorder volume   8 L BTPS @ 23°C (Using 12-s charts) 
Display   4 lines x 20 chs LCD 
Power supply   10v DC via PowerSAFE 
Maximum test duration   12 s dynamic (30-s VC) 
Leakage rate   0.038L/min max. @ 4L, 300g load 
Recording speed   20mm/sec over 12 sec 
Timing accuracy   ±1% of measured time (ATS 1994) 
Activation volume   0.04 L  
Operating temp. (physiological)  15 – 37°C 
Safety standards   CE mark, EN60601-1/2 























PO Box 414 Milwaukee WI 53201 USA 
Internet—http://ge-medicalsystems.com/ 
GE Medical Systems-Europe: Paris, France 
Fax: 33 1 30 70 94 35 
GE Medical Systems-Asia: 
Tokyo, Japan - Fax: 81 425 85 5490 
Hong Kong - Fax: 852 2559 3588 
CT LightSpeedTM Ultra 





Advanced slip ring design continuously rotates generator, 
tube, detector and data acquisition system around the 
patient. 
 
• Aperture: 70 cm 
• Tilt: ± 30° 
• Tilt Speed: 1°/sec. 
• Focus to Detector: 95 cm 
• Focus to Isocenter: 54 cm 
• Maximum SFOV: 50 cm 
• Rotational Speeds: 360° in 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 
2.0, 3.0 and 4.0 sec. 
• In-room Gantry controls (Front Right, Front Left, Back 
Right, Back Left) place the patient at the center of 
attention 
• Programmable start timer and display allow operator 
to start the exam from the patient’s side and safely 
exit the scan room 
• Breath-in lights with goal oriented countdown display 
improve patient breath hold compliance and avoid 
retakes 
• Remote gantry tilt controls at the operator console 
reduce trips between the scanner and the console 
 
Scan plane towards front of gantry for improved positioning 
access. 
 
Biopsy and interventional studies have been facilitated 
through a more streamlined gantry shroud, and bilateral 
table/gantry controls and gantry display that maximize 
maneuverability while working next to the gantry. 
 
Laser Alignment Lights: 
• Define both internal and external scan planes to  
± 1 mm accuracy. 
• Operate over full range of gantry tilt; activated any 
time during exam (with tube stationary). 
• Coronal light remains perpendicular to axial light as 
gantry tilts. 
 
Visual readout is easy to read from the table side or from 
the operator console. 
 
Table: 
• Single table, cantilever design with wide height range 
• Vertical Range: 51 cm to 107 cm 
• Vertical Scannable Range: 88 cm to 107 cm 
• Elevation Speeds: 5 mm/sec and 40 mm/sec 
• Horizontal Range: 170 cm 
• Horizontal Scannable Range: 170 cm metal-free 
(axial) and 160 cm metal-free (helical & Scout) 
• Horizontal Speed: Up to 100 mm/sec 
 
• Table automatically recenters on scan plane with 
changes in vertical position (after setting internal 
landmark with alignment lights on) 
• Table Load Capacity: 
- 180 kg (400 lb) with +/- 0.25 mm positional 
accuracy 
- 205 kg (450 lb) maximum allowed with normal 
operation and +/- 1 mm positional accuracy 
• Controls on gantry for elevation and cradle 
incrementation. Foot pedals on both sides of table for 




Performix Ultra Metal-Ceramic Tube Unit. Design 
optimized for exams requiring a large number of scans 
without tube cooling. 
• Heat Storage Capacity: 6.3 MHU 
• Heat Dissipation: 
- Anode (max) 840 KHU/min 
- Casing (cont) 300 KHU/min 
- Tube Unit: 6.9 kW continuous for 10 minutes 
• Dual Focal Spots: 
- Small Focal Spot:  0.7 (W) x 0.6 (L)  
nominal value (IEC 336/93) 
0.9 mm (W) x 0.7 mm (L)   
(traditional methodology) 
- Large Focal Spot:  
0.9 (W) x 0.9 (L)  
nominal value (IEC 336/93)  
1.2 mm (W) x 1.2 mm (L)  
(traditional methodology) 
• Maximum Power: 53.2 kW 
• Beam collimated to 55º fan angle. 
 
Average time to replace tube: < 10 hours 
 
High Voltage Generation 
• High-frequency on-board generator. Continuous 
operation during scan. 
• 53.2 kW output power. 
• kVp: 80, 100, 120, 140 kVp. 
• mA: 10 to 440 mA, 10 mA increments 
 
Maximum mA for each kVp selection: 
kVp  Max mA 
80  400 
100  420 
120  440 
140  380 
 
HiLight Matrix Detector: 
16 rows of 1.25 mm thickness, each containing 880 active 
patient elements; 32 reference elements. 
1.0-mm detector element spacing. 
 
7 modes of data output: 
- 1 x 1.25 mm (uses 1 row at center) 
- 4 x 1.25 mm (uses center 4 rows) 
- 4 x 2.5 mm (uses center 8 rows) 
- 4 x 3.75 mm (uses center 12 rows) 
- 4 x 5 mm (uses all 16 rows) 
- 8 x 1.25 mm (uses center 8 rows) 
- 8 x 2.5 mm (uses all 16 rows) 
 





Data Acquisition System: 
6144 available input channels. 
1640 Hz maximum sample rate. 
 
Effective analog to digital conversion range greater than 
two million to one. 
 
Scan/Control Unit: 
Located in base of Operator Console. 
Operator Console: 
• Size: 48 inch (1220 mm) wide x 40.5 inch (1030 mm) 
deep x 49.5 inch (1260 mm) high 
• Front and back work surfaces can be set during 
installation within a range of vertical heights that help 
accommodate a variety of siting requirements 
 
Host Computer: 
• Silicon Graphics, Inc. Octane Workstation 
• 300-MHz CPU with 2 MB cache. 
• 64-bit microprocessor. Dual R12K processor with 
Direct3D option.  
• RISC architecture 
• ≥ 17 SPECfp95 
• ≥ 9.3 SPECint95 
• 512 MB ECC SDRAM standard. 
 
Image Processor: 
• Silicon Graphics, Inc. IMPACT Graphics Engine 
• 4 MB TRAM (Texture Memory) 
• 60 Million trilinear interpolations per second 
 
Image Reconstruction Engine (Pegasus) 
• Custom-designed special purpose CT Image 
Generator 
• Pipelined parallel processing allows 12 views to be 
back-projected simultaneously 
• GE-patented IG ASICS provides 7.5 GFLOPS for 
back projection and IBO acceleration 
• 32-bit floating point data format 
• IG DSP’s rated at 1900 MFLOPS 
 
Software Architecture: 
• Software architecture based on industry standards 
and client-server design 
• Approximately 25 server processes running within 
system architecture at any time 




• Main system (host) disk drive: 
- High Performance Drive 
- 9 GB, 3.5 inch form factor 
- 10,000 RPM 
- UltraSCSI interface 
- Assigned to applications software and image 
files 
- Stores 3700 uncompressed 512 image files 
 
• Second system disk drive (Image Disk) 
- High Performance Drive 
- 9 GB, 3.5 inch form factor 
- UltraSCSI interface 
- Assigned to image files only 
- 9 GB stores 16,300 uncompressed 512 image 
files; brings total system storage to 20,000 
uncompressed 512 images 
 
• Scan data disk drive: 
- High Performance Drive 
- 18 GB, 3.5 inch form factor 
- UltraSCSI interface 
- Assigned to 2000 scan data files and calibration 
files 
- Each scan file approximately 6.14 MB 
 
• Standard MOD drive: 
- Magnetic Optical Disk Drive 
- Erasable, rewritable media 
- 2.3 GB, 3.5 inch form factor 
- Assigned to DICOM 3.0 format image file, scan 
file, and protocol file storage/retrieval  
(one file type per side) 
- Stores 4700 lossless JPEG compressed 512 
image files per side 
- Stores 350 uncompressed scan data files per 
side 
- Approximately 2 sec storage or retrieval time per 
512 image 
- Off-line retrieval of image and scan files. Images 
may be viewed as soon as they are restored 
from MOD 
 
• CD-ROM drive: 
- Integrated in front of operator console for easy 
access 
- 32X or greater rotational mode 
- 0.65 GB, 5.25 inch half height form factor 
- Assigned to Sherlock on-line computerbased 
training and loading software 
 
• 2 x CRT Color monitors*: 
- 21 inch diagonal width 
- 1280 x 1024 dot resolution 
- Non-interlaced, flicker-free presentation 
- 76 kHz Horizontal deflection frequency 
- 72 Hz Vertical deflection frequency 
- Sync on green 
 
• 2x Flat Screen Color Monitors: 
- 46cm (18 inch) LCD monitors 
• Scan control keyboard assembly with intercom 
speaker, mic and volume controls; English language 
keyboard 
• Global modem to allow Insite connectivity. 
• 3-Button Mouse 
• 3-Button Trackball 
 
Image Networking: 
• Standard auto-configuring 
• 100BaseT/10BaseT Ethernet (UTP connection) 
• Direct network connection; multi-suite Ethernet card 
not required for gateway out of suite 
• Protocols supported: 
- DICOM 3.0 network send (one IP address at a 
time) & receive, pull/query, and storage 
commitment push; 
- AdvantageNet (GenesisNet) point-to-point 
- send, receive and pull/query (no broadcast); 
- InSite point-to-point; 












Paper II, Table E1 
 
Table E1. Adjusted Cox regression analysis. Risk for lung cancer in all subjects, N=852.  
      
  ‘HRR 95% CI    
Sex 1.10 0.60-2.00    
Age 1.02 0.99-1.06    
Pack Years 1.01 1.00-1.02    
Current smokers 0.74 0.42-1.30    
Age of onset of smoking 0.99 0.92-1.05    
^PB FEV1 pp 0.95 0.81-1.12    
§BMI (kg/m^2) 0.92* 0.87-0.98    
Asthma 1.18 0.60-2.35    
~AECOPD, 1 or more 2.55* 1.25-5.21    
AECOPD#asthma 0.34* 0.11-0.98    
‘Hazard Rate Ratio, ^Post‐bronchodilator FEV1 percent predicted, divided by 10. §Body mass index, ~Acute exacerbations 




Table E2. Adjusted Fine & Gray regression analyses. Mortality as competing risk. Probability of 
having lung cancer in COPD patients with and without asthma 
 No asthma  Asthma    
 ‘SHRR 95 % CI ‘SHRR 95 % CI   
  N = 430   N = 422     
Sex 1.65 0.72 - 3.77 0.74 0.31 - 1.79   
Age 1.01 0.99 - 1.04 1.00 0.96 - 1.03   
Pack Years 1.01 0.99 - 1.03 1.01 0.99 - 10.3   
Current smokers 0.67 0.30 - 1.50 0.81 0.32 - 2.05   
Age of onset of smoking 0.95  0.84 - 1.07 1.01 0.93 - 1.10   
^PB FEV1 pp 1.05 0.84 - 1.30 1.02 0.80 - 1.30   
§BMI (kg/m^2) 0.89** 0.82 - 0.97 0.98 0.91 - 1.05   
~AECOPD, 1 or more 2.60** 1.21 - 5.56 0.88 0.38 - 2.05   
‘Sub-Hazard Rate Ratio, ^Post‐bronchodilator FEV1 percent predicted, divided by 10. §Body mass index, ~Acute 















Paper III, Table E1 
 
Table E1. Positive predictive value (PPV) and negative predictive value (NPV) as well as sensitivity 
and specificity of the COPD-LUCSS and the NLST criteria for lung cancer among COPD patients 
  PPV NPV Sensitivity Specificity 
COPD-LUCSS, (95% C.I.) 9% (7-11) 96% (93-98) 70 % 51 % 
NLST criteria, (95% C.I.) 10% (7-14) 95% (93-97) 48 % 70 % 
COPD-LUCSS: Chronic Obstructive Pulmonary Disease – Lung Cancer Screening Score 





Table E2. Logistic regression showing association of COPD-LUCSS and lung cancer as well as NLST 
criteria and lung cancer in smokers with COPD 
 Ever-smokers with COPD 
  N=422 
COPD-LUCSS 2.5* (1.1-5.8) 
NLST 2.2(1.0-4.7) 
Data are presented as Odds ratio (95% CI). High Risk vs Low Risk of the COPD-LUCSS (chronic obstructive pulmonary 




Table E3. Distribution of lung cancers according to the COPD-LUCSS and the NLST criteria, with 
ten- and eight-years follow-up. 
 
 
Lung cancer followed 
ten years 
Lung cancer followed 
eight years  
COPD-LUCSS No Yes No Yes Total 
Low risk 201 9 202 8 210 
High risk 191 21 193 19 212 
Total 393 30 395 27* 422 
      
 
Lung cancer followed 
ten years 
Lung cancer followed 
eight years  
NLST criteria No Yes No Yes Total 
Low risk 275 15 276 14 290 
High risk 117 15 119 13 132 
Total 393 30 395 27* 422 
* For the logistic regression analysis, the follow-up was set to eight years to enable the same follow-up for each individual. 
Cox regression enables censoring. Ten years follow-up was therefore used in the Cox regression. There were 30 cancer cases 
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Acute exacerbations of COPD and risk of lung cancer in COPD patients with and without 
coexisting asthma.   
Ane Aamli Gagnat1, Miriam Gjerdevik2, Stein Atle Lie3, Amund Gulsvik1, Per Bakke1, Rune1,4 
Nielsen. 
1: Department of Clinical Science, University of Bergen, Norway 
2: Department of Global Public Health and Primary Care, University of Bergen, Norway 
3: Department of Clinical Dentistry, University of Bergen, Norway. 





Compared to healthy smokers, smokers suffering from COPD have an increased risk of lung 
cancer (1). Emphysema (2) and airway obstruction (1) increase the risk of lung cancer, but 
there is limited knowledge on how other features of COPD, such as acute exacerbations in 
COPD (AECOPD) affect lung cancer incidence.  
 
Chronic inflammation is central to the development of COPD (3). Inflammation is further 
thought to play an essential part in the pathogenesis of lung cancer in COPD patients (4). 
Since both local and systemic chronic inflammation is a characteristic of COPD exacerbations 
(5, 6) (7), one might hypothesize that acute exacerbations in COPD increase the risk of lung 
cancer. 
 
Few studies have examined AECOPD and the risk for lung cancer, and these studies show 
conflicting results (7, 8). In a nested case-control study from the COPDGene cohort, patients 
with COPD with incident lung cancer reported a higher frequency of exacerbations 12 
months prior to study enrolment (8). In a study of 433 COPD patients and 279 healthy 
controls, AECOPD was not related to increased incidence of lung cancer during nine years of 
follow-up (7).  
 
Patients with coexisting asthma have often been excluded from COPD studies. This was also 
the case with the study of Husebø et al. (7). COPD patients with coexisting asthma may have 
a different exacerbation phenotype compared to COPD patients without coexisting asthma 
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(9). Hence, the risk of lung cancer from AECOPD might vary by the presence of a coexisting 
asthma (10). 
 
We had access to a population-based cohort of subjects with COPD, which includes 
information regarding asthma diagnosis as well as AECOPD the year before inclusion. This 
information was linked with data from the Cancer Registry of Norway (11) in order to 1) 
explore whether AECOPD is associated with an increased risk of lung cancer during ten years 
follow-up, and 2) whether the risk of lung cancer due to AECOPD differs based on coexisting 
asthma.  
 
Materials and Methods  
Prior to enrolment, information was given and written informed consent obtained from all 
study subjects. The study was reviewed and approved by the Western Norway Regional 
Committee for Medical and Health Research Ethics, reference number 2010/2575/REK vest.  
 
Study population 
The subjects in the current analyses were all participants in the GenKOLS study (Genetic 
COPD study) conducted between January 2003 and January 2005 in Bergen, Norway. Details 
on the GenKOLS population are presented elsewhere (12). GenKOLS was a case-control 
study, and the subjects in the current analyses comprise the COPD cases only. Participants 
were 40-85 years of age and had a smoking history of at least 2.5 pack-years at baseline. 
COPD was diagnosed when post-bronchodilator FEV1/FVC was <0.70 and FEV1 < 80 % 
predicted. Baseline examinations included a detailed questionnaire on smoking habits, 
respiratory symptoms, and disease history, as well as pulmonary function tests. We also 
obtained incidence data from the Cancer Registry of Norway (11) throughout the year 2013. 
All subjects with a cancer diagnosis before inclusion were excluded from the analyses. Due 
to missing information on emigration date, also four individuals that emigrated during 
follow-up were excluded. 
 
Main variables  
Lung cancer incidence was the primary outcome variable. We retrieved information on the 
study participants who developed lung cancer from January 2003 through December 2013 
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from the Cancer Registry of Norway, which contains data on all individuals in Norway 
diagnosed with cancer (11). Registration is regulated by law, and registration of patients is 
mandatory both for pathologists and clinical doctors, with a near 100 % completeness (13). 
Lung cancer was identified in the registry by the ICD-10-code C34. The data from the Cancer 
Registry included time of diagnosis and histologic classification of the cancer.  
 
Acute exacerbations of COPD (AECOPD) was the main predictor of interest. AECOPD was 
defined as events where courses of antibiotics were administered due to lung disease in the 
last 12 months preceding inclusion.  
 
Participants were considered to have a history of asthma if they gave affirmative answers to 
both: “Have you had asthma?" and “if yes, was this confirmed by a doctor?” 
 
Other variables  
Smoking status was defined as current status at inclusion. Pack-years of tobacco smoking 
was defined as (number of cigarettes smoked per day/20) x number of years smoked. We 
also recorded age at onset of smoking. Educational level, height, weight, and pulmonary 
function tests were measured at inclusion (14). Spirometries were performed according to 
the American Thoracic Society standards (15). Local reference values for FEV1 and FVC were 
used (16). The date of death was obtained by linkage to the Norwegian National Cause of 
Death Registry (17). Patients were followed until a diagnosis with lung cancer, date of death, 
or end of follow-up in December 2013, whichever came first. 
 
Statistical analyses 
Since only eight individuals developed lung cancer in the group with two or more 
exacerbations in the preceding year, AECOPD was analysed as a dichotomous variable (0 vs. 
1 or more exacerbations). The Kaplan-Meier methods were used to calculate and plot 
probabilities for developing lung cancer. To quantify differences in the risk of developing 
lung cancer, we performed Cox proportional hazards regression and report hazard rate 
ratios (HRR) (18). Covariates in the adjusted analyses were sex, age, pack-years, age of onset 
of smoking, smoking status at inclusion, body mass index (BMI), and FEV1. The interaction 
between AECOPD and asthma on lung cancer was also tested. 
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Furthermore, analyses stratified by asthma were presented. To take mortality into account, 
as a competing risk, we also performed Fine and Gray competing risk analyses for the 
probability of developing cancer. The results from the Fine and Gray model (19), presented 
as sub-hazard rate ratios (SHRR), are presented in the online supplement. 
 
All analyses were performed using STATA version 16. (StataCorp. TX, USA). A two-sided 




Altogether, there were 852 COPD patients included in the study, of which 38.4 % were 
women. The mean age was 65.1 (SD=10.1) years, 30.5 % had one or more exacerbation 
during the last 12 months before inclusion, and 49.5 % reported a history of asthma at 
inclusion. COPD patients with a history of asthma comprised more women, had a lower 
smoking consumption in terms of pack-years, had more exacerbations 12 months prior to 
inclusion, and a lower lung function in terms of FEV1 in percent predicted than COPD 
patients without a history of asthma (Table 1). 
 
For the entire sample, 8.8 % of the COPD patients with and 5.9 % of the COPD patients 
without exacerbations were diagnosed with lung cancer. Average time from inclusion to lung 
cancer diagnosis was 4.5 years (range: 43 days to 10.4 years), which did not differ 
significantly between those with and without exacerbations.  
 
In unadjusted Cox regression analyses on the entire sample, increasing age and decreasing 
BMI were significantly associated with the risk of lung cancer, the HRR being 1.03 (95% CI 
1.00-1.06) per year, and HRR=0.93 (95% CI 0.88-0.99) per kg/m2, respectively. Exacerbation 
status at inclusion was also related to the risk of lung cancer (borderline non-significant). The 
HRR for lung cancer in those with one or more exacerbations as compared to no 
exacerbations 12 months before inclusion was 1.58 (95% CI 0.93-2.67).  
 
In COPD patients without a history of asthma, those with one or more exacerbations had a 
higher probability of lung cancer than those without exacerbations (Figure 1, A), while for 
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COPD patients with a history of asthma, the probability of lung cancer did not differ between 
those with and without exacerbations (Figure 1, B).  
 
For COPD patients without a history of asthma, we found that those with exacerbations had 
an HRR for lung cancer of 2.77 (95% CI 1.39-5.52) compared to those without exacerbations. 
For COPD patients with asthma, the corresponding number was 0.90 (95% CI 0.40-2.05) 
(Table 2). When adjusting for sex, age, smoking status and consumption, FEV1, and BMI at 
inclusion, the risk ratio for lung cancer in those with exacerbations (compared to those 
without) remained significantly increased in the non-asthma group and was still insignificant 
in those with a history of asthma (Figure 2). 
 
Adding an interaction term between asthma and exacerbation status in the adjusted Cox 
regression analysis on the entire sample, we found that the interaction term reached level of 
significance. This shows that there is an additional effect of exacerbations for patients 
without asthma (Table E1, online supplement). 
 
The Fine and Gray competing risk model for the probability of developing lung cancer, taking 
patient mortality into account, gave virtually the same results as the Cox-regression analysis. 
Results are presented in the online supplement (Table E2).  
 
The histological subtypes of lung cancer comprised 33.9 % adenocarcinoma, 22.0 % 
squamous cell, 10.2 % small cell lung cancer, 25.4 % unspecified non-small cell lung cancer, 
and 8.5 % had unknown histology type. No relationship between AECOPD and histological 
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Discussion  
The main finding of this study on subjects with COPD followed for ten years was that 
AECOPD was only significantly associated with increased risk of lung cancer in COPD patients 
without coexisting asthma. The association was independent of sex, age, BMI, lung function, 
pack-years, age of onset of smoking, and smoking status at baseline.  
 
Our findings are in line with Carr et al. in showing an association between AECOPD and lung 
cancer risk (8). Carr et al. followed a cohort of subjects with and without COPD. When 
exploring the association between AECOPD and lung cancer in COPD cases only, they were 
not able to produce significant results. They followed their cohort for an average of 5.7 
years, of which 24 % had < 5 years follow-up, and 10 % of their subjects had no follow-up. 
Hence, they expected some lung cancers to be unreported and did not know their survival 
outcomes (8).  In the present study, we had ten years of follow-up and access to the Cancer 
Registry of Norway with practically 100 % coverage. Another study looking at several risk 
factors for lung cancer in COPD found no association between AECOPD and risk of lung 
cancer (7). They detected 32 lung cancer cases and did not report the number of 
exacerbations. The lack of an association in their study could be due to small numbers and 
low statistical power.  
 
We observed a significant association between AECOPD and lung cancer risk only in COPD 
patients without asthma. To our knowledge, this is the first study to explore whether there is 
a difference between the effect of AECOPD on lung cancer in COPD patients based on 
coexisting asthma.  
 
This finding could have several explanations. First, one recent retrospective study found that 
coexisting asthma in COPD patients is associated with decreased risk of lung cancer (10). This 
could indicate that COPD patients with coexisting asthma represent a phenotype caused by 
different mechanisms, and therefore, a reduced risk of lung cancer. Their study did, 
however, have several weaknesses. COPD was defined without spirometry, and they were 
not able to adjust for lung function in the statistical analyses. They also lacked information 
on tobacco exposure, which might explain lower lung cancer risk for those with asthma.  
Second, several studies have found a decreased risk of lung cancer with inhaled steroids (7, 
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20-22). This could be due to reduced airway inflammation, and that decreased cell turnover 
lowers the risk for propagation of genetic errors (23). Patients with coexisting asthma might 
have used more inhaled steroids, and COPD patients with clinical features similar to asthma 
are found to respond better to corticosteroids than COPD patients without (24).  Third, 
inflammation is an essential part of the pathogenesis in lung cancer development in patients 
suffering from COPD (4). COPD is considered a systemic disease (25) in which the frequent 
exacerbations phenotype is associated with increased systemic inflammation (7). AECOPD 
have different triggers, clinical manifestations, biomarkers, comorbidities, and exacerbation 
frequencies (9). Neutrophilic inflammation driven by CD8+ T-cells are often seen in COPD, 
whereas inflammation in asthma patients more often is eosinophilic and mediated by CD4+ 
T-cells (26). One might hypothesize that the neutrophilic inflammation increases lung cancer 
risk more than the eosinophilic. Fourth, triggers such as viruses and bacteria are thought to 
cause most exacerbations (27, 28). Some bacteria and more viruses play an essential part in 
cancer development of other types of cancer (29, 30). It could be that some bacteria or 
viruses lead to cancer development also in the lungs. We do not know whether different 
COPD phenotypes have different triggers to AECOPD. Fifth, tobacco exposure is a prevalent 
risk factor for both lung cancer and COPD. COPD patients with asthma smoked less than 
COPD patients without asthma (Table 1). It could be that the chronic inflammation and 
enzymatic imbalance caused by tobacco is less present in asthma patients. Also, other 
possible confounders should be considered. The group without asthma had higher 
educational attainment than the group with asthma, implying no beneficial effect on lung 
cancer risk from education (Table 1). We adjusted for pack-years, age of onset of smoking, 
smoking status, age, sex, and lung function in the adjusted analyses, but residual 
confounding cannot be ruled out. 
 
For the statistical analyses in this article, we used Cox-proportional hazards regression. Using 
the increasingly popular Fine and Gray competing risk regression, taking patient mortality 
into account, we found virtually the same as using Cox-regressions (Table E2). Still, one could 
argue that competing risk models are better suited for studying the clinical prognosis of the 
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There are several strengths in this study. First, it is a sizeable single-centre study that allows 
for extensive adjustment for relevant confounders. Second, participants were not sampled 
from a cancer screening trial, but a community-based sample followed for more than 8000 
person-years. Third, it is a prospective study in which all lung cancers were incident cases 
diagnosed after baseline measures of exacerbations. Fourth, cancer diagnosis was taken 
from the Cancer Registry of Norway, which has close to a 100 % inclusion rate and provide 
histology verified diagnosis (31). Fifth, spirometry was performed by all participants, and 
chronic airway obstruction verified in all subjects with COPD. 
 
The present study also has some limitations. First, the GenKOLS study was initially designed 
as a case-control study to examine subjects with COPD. We, therefore, have few cancer 
cases compared to those sampled in screening trials. Due to small numbers of lung cancer, 
the lack of association between AECOPD and histological subgroups of lung cancer should be 
interpreted with care. Second, the exacerbations were questionnaire-based, and we do not 
have data on the type of exacerbation or samples of eosinophils. Third, the asthma diagnosis 
was questionnaire-based and presented history of asthma as opposed to a current clinical 
diagnosis. It might be that some of the subjects received a wrong diagnosis earlier in life. The 
prevalence of asthma in this population of subjects with COPD is in line with other 
epidemiological studies (32-35), but higher than in clinical trials (36, 37). Fourth, never-
smokers were not included in the study, which prevented us from generalizing the findings 
to a never-smoking population. We did, however, include tobacco consumption down to 2.5 
pack-years. Fifth, we did not include GOLD stage I, which in some studies have shown to 
have the highest incidence of lung cancer (38). Sixth, we used a fixed ratio for COPD 
diagnosis, which might lead to over-diagnosis in elderly subjects when compared to the 
lower limit of normal. 
 
Clinical relevance 
We know that COPD is a risk factor for lung cancer (39). Nevertheless, most randomized 
control trials have had recruitment criteria based on age and smoking history alone (40-45). 
This study suggests that AECOPD and asthmatic features of COPD should be considered 
when evaluating those at higher risk. More studies, including validated information on acute 
exacerbations and COPD patients with coexisting asthma, are needed to better understand 
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which mechanisms link COPD and lung cancer. As we learn more about the clinical 
phenotypes of COPD, these might help target those COPD patients at the highest risk and 
determine who to include in screening trials.   
 
Conclusion 
Exacerbations of COPD is associated with an increased risk of lung cancer in those without 
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Tables and figures 
 
Table 1. Baseline characteristics by asthma    
  No asthma Asthma P-value   
Subjects, n 430 422    
Sex, female (%) 30.5 46.5 <0.001   
Years of age, mean (SD) 64.9 (10.2) 65.4 (10.0) 0.504   
Current smokers (%) 47.0 45.3 0.615   
Pack years, median (25/75 percentile) 31.0 (21/44) 25.9 (18/39) <0.001   
Age of onset of smoking, mean (SD) 18.4 (4.5) 18.9 (5.8) 0.468   
~AECOPD, mean (SD) 0.3 (0.8) 0.8 (1.5) <0.001   
Lung cancer (%) 7.7 5.9 0.311   
§BMI (kg/m^2), mean (SD) 25.3 (4.8) 25.7 (5.2) 0.528   
Education (%)  0.002   
Primary 26.4 35.8    
Secondary 59.6 55.8    
University 14.0 8.4    
^PB FEV1 pp, mean (SD) 54.6 (17.3) 47.0 (17.0) <0.001   
~Acute exacerbations in COPD, §Body mass index, ^Post‐bronchodilator FEV1 percent predicted. 
    
 
 
Table 2. Unadjusted Cox regression analyses. Risk for lung cancer in COPD patients with 
and without asthma 
     
     
 No asthma  Asthma  
  ‘HRR 95 % CI ‘HRR 95 % CI 
Sex 1.72 0.75 - 3.97 0.83 0.38 - 1.82 
Age 1.03 0.99 - 1.07 1.02 0.98 - 1.07 
Pack Years 1.01 0.99 - 1.03 1.01 0.99 - 1.03 
Current smokers 0.71 0.35 - 1.41 0.84 0.38 - 1.86 
Age of onset of smoking 0.96 0.88 - 1.05 1.02 0.95 - 1.08 
^PB FEV1 pp 0.83 0.69 - 1.01 0.91 0.72 - 1.16 
§BMI (kg/m^2) 0.91* 0.84 - 0.98 0.96 0.88 - 1.04 
Education 0.70 0.40 - 1.23 0.62 0.31 - 1.21 
~AECOPD, 1 or more 2.77** 1.39 - 5.52 0.90 0.40 - 2.05 
‘Hazard Rate Ratio, ^Post‐bronchodilator FEV1 percent predicted, divided by 10. §Body mass index, ~Acute 
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Figure 1. Survival estimates for lung cancer by AECOPD in COPD patients without (A) and 





Figure 2. Unadjusted and adjusted Cox regression analyses. Risk for lung cancer in COPD 
patients without and with asthma 
 
 
Adjusted for sex, age, pack-years, age of onset of smoking, smoking status, BMI, and FEV1 
 
 






Table E1. Adjusted Cox regression analysis. Risk for lung cancer in all subjects, N=852.  
      
  ‘HRR 95% CI    
Sex 1.10 0.60-2.00    
Age 1.02 0.99-1.06    
Pack Years 1.01 1.00-1.02    
Current smokers 0.74 0.42-1.30    
Age of onset of smoking 0.99 0.92-1.05    
^PB FEV1 pp 0.95 0.81-1.12    
§BMI (kg/m^2) 0.92* 0.87-0.98    
Asthma 1.18 0.60-2.35    
~AECOPD, 1 or more 2.55* 1.25-5.21    
AECOPD#asthma 0.34* 0.11-0.98    
‘Hazard Rate Ratio, ^Post‐bronchodilator FEV1 percent predicted, divided by 10. §Body mass index, ~Acute 
exacerbations in COPD, # interaction between AECOPD and asthma * p<0.05, ** p<0.01.  
 
 
Table E2. Adjusted Fine & Gray regression analyses. Mortality as competing risk. Probability 
of having lung cancer in COPD patients with and without asthma 
 No asthma  Asthma    
 ‘SHRR 95 % CI ‘SHRR 95 % CI   
  N = 430   N = 422     
Sex 1.65 0.72 - 3.77 0.74 0.31 - 1.79   
Age 1.01 0.99 - 1.04 1.00 0.96 - 1.03   
Pack Years 1.01 0.99 - 1.03 1.01 0.99 - 10.3   
Current smokers 0.67 0.30 - 1.50 0.81 0.32 - 2.05   
Age of onset of smoking 0.95  0.84 - 1.07 1.01 0.93 - 1.10   
^PB FEV1 pp 1.05 0.84 - 1.30 1.02 0.80 - 1.30   
§BMI (kg/m^2) 0.89** 0.82 - 0.97 0.98 0.91 - 1.05   
~AECOPD, 1 or more 2.60** 1.21 - 5.56 0.88 0.38 - 2.05   
‘Sub-Hazard Rate Ratio, ^Post‐bronchodilator FEV1 percent predicted, divided by 10. §Body mass index, ~Acute 
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1 |  INTRODUCTION
Guidelines on screening programs for lung cancer in smokers 
recommend using low‐dose computed tomography (LDCT) 
of the chest.1 These recommendations are mainly based on 
the National Lung Cancer Screening Trial (NLST), which 
observed that using LDCT might reduce lung cancer mortal-
ity by at least 20%.2 The NLST screening selection criteria 
included individuals between 55 and 74 years of age with a 
smoking history of at least 30 pack years. The subjects were 
either current smokers or had quit within the last 15 years.
Since the NLST article was published in 2011, several 
studies have tried to improve the NSLT criteria.3-5 De Torres 
et al5 also created a score, the COPD‐LUCSS (chronic ob-
structive pulmonary disease—lung cancer screening score). 
This score included the presence of emphysema, age above 
60 years, pack years above 60 and body mass index (BMI) 
below 25 as predictors and found that this score predicted 
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Abstract
Introduction: Based on the National Lung Cancer Screening Trial (NLST), guide-
lines on screening programs for lung cancer have recommended low‐dose computed 
tomography (LDCT). De Torres et al made a score for COPD patients (COPD‐
LUCSS) to improve their selection criteria.
Objective: To examine and compare the discriminating value of both scores in a 
community‐based cohort of COPD patients.
Methods: Four hundred and twenty‐two ever‐smokers with COPD from the 
GenKOLS study in Bergen were merged with the Cancer Registry of Norway. We 
divided the patients into groups of high and low risk according to the COPD‐LUCSS 
and the NLST criteria. Cox regression and logistic regression were used to analyse 
the associations between the scores and lung cancer. We used Harrell’s C and area 
under the curve (AUC) to estimate discriminating values and to compare the 
models.
Results: Hazard ratio for the high risk vs the low risk in the COPD‐LUCSS was 3.0 
(1.4‐6.5 95% CI), P < 0.01. Hazard ratio for the NLST criteria was 2.2 (95% CI 
1.1‐4.5), P < 0.05. Harrell’s C was 0.63 for the COPD‐LUCSS and 0.59 for the 
NLST selection criteria. AUC was 0.61 for COPD‐LUCSS and 0.59 for NLST crite-
ria. Comparing tests showed no differences (P = 0.76).
Conclusion: Although the COPD‐LUCSS and the NLST criteria were associated 
with increased risk of lung cancer, the AUC and Harrell's C values showed that these 
models have poor discriminating abilities in our cohort of COPD patients. The 
COPD‐LUCSS was not significantly better than the NLST criteria.
K E Y W O R D S
COPD, epidemiology, lung cancer, screening
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lung cancer in patients with chronic obstructive pulmo-
nary disease (COPD) better than the NLST selection cri-
teria.5 The authors were able to replicate their findings in 
an independent study population. However, the COPD pa-
tients were recruited from two screening cohorts. It may be 
questioned to which extent their findings are valid in the 
COPD population at large. They followed their cohort for 
3‐4 years, and the long‐term benefits of their criteria are 
still unknown.
We had access to a community‐based sample of ever‐
smokers with COPD, all examined with computed tomogra-
phy of the chest in 2003‐2005. This data set was merged with 
data from the Cancer Registry of Norway,6 providing data on 
lung cancer incidence from 2003 to 2013, ie, the population 
was followed for 8‐10 years. We aimed to examine and com-
pare the discriminating ability of the COPD‐LUCSS and the 
NLST criteria in our population‐based sample of ever‐smok-
ers with COPD.
2 |  MATERIALS AND METHODS
2.1 | Study population
Patients were selected from the GenKOLS (Genetic COPD) 
study in Bergen, Norway. The GenKOLS study recruited 
subjects from two general population studies and a hospital 
patient register.7 The GenKOLS study was conducted from 
January 2003 to January 2005.8 Subjects were 40‐85 years 
of age and had a smoking history of 2.5 pack years or more 
at baseline. COPD was diagnosed when post‐bronchodila-
tor FEV1/FVC was <0.70 and FEV1 was <80% predicted. 
The examination at baseline in 2003/05 included chest CT, 
pulmonary function tests and questionnaires on smoking 
habits. The GenKOLS data were merged with the Cancer 
Registry of Norway6 with complete data through 2013 
(n = 422). Details on the study population are described 
elsewhere.9
2.2 | Quantitative interpreted CT
CT scans were performed with a GE LightSpeed Ultra 
CT scanner at full inspiration using 1‐mm slice thickness 
at 20‐mm intervals. The extent of emphysema was as-
sessed using the percentage of lung voxels with X‐ray at-
tenuation values (low‐attenuation areas, %LAA) less than 
−950 Hounsfield units (%LAA950). This cut‐off has been 
shown to be accurate for the CT acquisition technique.10 
Percent emphysema for the whole lung was calculated. 
Emphysema was measured as %LAA950. These meas-
urements were taken from a previous study on the same 
population examining emphysema and mortality.11 In our 
study, those with LAA 3% and above are considered to 
have emphysema present.
2.3 | The Cancer Registry of Norway
All individuals in Norway diagnosed with cancer of any type 
are registered in the Cancer Registry of Norway.6 Registration 
is obligatory by law, by both clinical doctors and pathologists, 
thus securing completeness of the registry.12 The inclusion 
rate is close to 100%. Subjects who developed cancer dur-
ing the follow‐up in our study were identified in the Cancer 
Registry of Norway. ICD‐10‐code C34 defined lung can-
cers. The data obtained included the time of diagnosis. The 
Norwegian Data Inspectorate, the Norwegian Directorate of 
Health and Social Services the Regional Ethical Committee 
for Medical Research gave permission to use the data.
2.4 | Other variables
Smoking variables included current smoking status, pack 
years and age at onset of smoking, all self‐reported at base-
line. Spirometries were performed according to the American 
Thoracic Society standards.13 Reference values for FEV1 
and FVC were local.14 COPD patients were categorized into 
grades 2‐4 according to GOLD2007 classification, as defined 
by FEV1 in the percent predicted.15
2.5 | Statistical analysis
The patients were divided into groups of high and low risk 
 according to the COPD‐LUCSS and the NLST criteria1,2 
(Table 1). The association between the COPD‐LUCSS and 
lung cancer, as well as the NLST criteria and lung cancer, was 
assessed by Cox proportional hazards regression, followed by 
Harrell’s C concordance statistics estimates to measure dis-
crimination.16 In order to compare the models objectively, we 
also used logistic regression with 8 years of follow‐up. We used 
lung cancer as the outcome, followed by post hoc receiver oper-
ating curve (ROC) and intra model area under the curve (AUC) 
comparisons for the COPD‐LUCSS and the NLST scores.17 To 
obtain the ROC curves and AUC comparisons, we used the 
Stata commands lroc and roccom. This method provides a χ2 
test for the difference in AUCs between two estimated models 
using the same set of observations. An AUC varies between 
0 and 1. A value of 1 indicates a perfect diagnostic tool with 
100% sensitivity and 100% specificity, whereas an AUC of 0.5 
implies no discrimination. All analyses were performed using 
STATA 13 (StataCorp. 2013. Stata Statistical Software: Release 
13. College Station, Texas: StataCorp LP), and the two‐sided 
significance level was set to 0.05 for all analyses.
3 |  RESULTS
A total of 422 subjects were included in this study. 
Characteristics are described in Table 2. Applying the 
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COPD‐LUCSS, 212 of the 422 individuals were ascribed 
to the high‐risk category and 210 to the low‐risk category. 
Of those in the high‐risk group, 21 individuals (9.9%) were 
diagnosed with lung cancer during the follow‐up. The cor-
responding figures in the low‐risk group were 9 individuals 
(4.3%). Using the NLST criteria, 132 of the 422 subjects were 
characterized as high risk and 290 as low risk. In the high‐
risk group, 15 (11.4%) got lung cancer. In contrast, 15 out of 
290 (5.2%) were diagnosed with lung cancer in the low‐risk 
group. Positive predictive values (PPV) and negative predic-
tive values (NPV), as well as sensitivity and specificity, are 
shown in the supporting information (Table S1).
Cox regression analysis showed that both the COPD‐ 
LUCSS and the NLST criteria were significantly associated 
with lung cancer in our population of ever‐smokers. Hazard 
ratio for the high risk vs the low risk in the COPD‐LUCSS 
was 3.0, 95% confidence interval (CI) was 1.4‐6.5, P < 0.01. 
Hazard ratio for the NLST criteria, high risk vs low risk, 
was 2.2, 95% CI 1.1‐4.5, P < 0.05. Harrell’s C concordance 
statistic estimates were 0.63 for the COPD‐LUCSS and 0.59 
for the NLST selection criteria.
Logistic regression with a follow‐up of 8 years showed 
similar results as the Cox regression (Table S2). The AUC 
values were 0.61 for the COPD‐LUCSS and 0.59 for the 
NLST selection criteria (Figure 1). There was no signif-
icant difference between the AUC values of these criteria, 
P = 0.76. The distribution of lung cancers in each group is 
shown in the supporting information Table S3.
4 |  DISCUSSION
In this study, that comprised a community‐based cohort of 
ever‐smokers with COPD, we observed that: (1) although 
both the COPD‐LUCSS and the NLST selection criteria are 
significantly associated with an increased risk of lung cancer, 
the models do not discriminate well; (2) there were no signif-
icant differences in the ability of discrimination between the 
T A B L E  1  Variables included in the COPD‐LUCSS and in the NLST selection criteria
COPD‐LUCSS
BMI < 25 1 point
Pack years history > 60 2 points
Age > 60 years‐old 3 points
Radiological emphysema: yes 4 points
Total 10 points
NLST inclusion criteria
Pack years > 30
Age 55‐74 years
Current smoker or quit smoking within the previous 15 years
Abbreviations: COPD‐LUCSS, Chronic Obstructive Pulmonary Disease—Lung Cancer Screening Score; NLST, National Lung Cancer Screening Trial.
Notes: In the COPD‐LUCSS, the low‐risk category includes those with 0‐6 points. The high‐risk category includes those with 7‐10 points.
In the NLST, those with all the mentioned criteria are considered as high risk. Those with two or less of the mentioned criteria are considered low risk.
Female Male
Subjects, n 151 271
Years of age, mean (SD) 62.1 (8.9) 65.1 (9.4)
Current smokers (%) 53.6 46.5
Pack years, median (25/75 percentile) 22.5 (16/33) 30.8 (21/44)
Age of onset of smoking, mean (SD) 20.2 (6.3) 17.4 (4.0)
Emphysemaa, mean (SD) 9.7 (11.8) 12.5 (11.8)
Lung cancer (%) 6.6 7.4
BMIb (kg/m2), mean (SD) 25.1 (5.7) 25.8 (4.2)
PB FEV1c pp, mean (SD) 53.2 (16.2) 52.8 (17.3)
aEmphysema measured in % pe950. 
bBody mass index. 
cPost‐bronchodilator FEV1 percent predicted. 
T A B L E  2  Characteristics by sex
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COPD‐LUCSS and the NLST criteria; (3) even in the low‐
risk groups of both the criteria, about 4%‐5% of the patients 
developed lung cancer.
Our finding that the COPD‐LUCSS is associated with 
lung cancer among COPD patients is in line with the results 
of de‐Torres et al5 We have extended the current knowledge 
by showing that similar results are found in a COPD popula-
tion that is not sampled through lung cancer screening pro-
grams and therefore apply to the COPD population at large. 
Moreover, we had a follow‐up of 10 years, while de‐Torres 
followed their cohort for 5 years. Compared with the pop-
ulations used by de Torres et al,18,19 our COPD population 
was older (mean age 64 years vs 61 years), had a lower over-
all cigarette consumption (27 pack years vs 43 and 53 pack 
years) had a lower mean FEV1 (53% of predicted vs 79% and 
71% of predicted).
The variables in the COPD‐LUCSS were selected through 
Cox regression and the cut‐off values were selected by divid-
ing each variable into quartiles or quintiles. The best cut‐off 
values were chosen by visual assessment.5 Further, de Torres 
et al found that the COPD‐LUCSS was better than the NLST 
selection criteria. This was examined by visual comparison 
of the Kaplan‐Meier curves. However, they did not test this 
statistically. We used an objective test showing no significant 
difference in our data. Moreover, the AUC values remained 
between 0.59 and 0.61, indicating approximately the same 
poor discriminating values for both the COPD‐LUCSS and 
the NLST criteria.20 Although both criteria are associated 
with lung cancer, it should be noted that 30% and 50% of the 
lung cancers occurred in the low‐risk group. This is illus-
trated in Table E3. One could therefore argue that the models 
in their current form should not be used to select individuals 
for lung cancer screenings.
We aimed to study the discriminative abilities of the 
scores, as measured by AUC and Harrell's C. Discrimination 
is useful in a diagnostic setting to separate people with dis-
ease from people without.21 A predictive model with poor 
discriminative ability will not be of any use even with good 
calibration. Hence, we did not assess calibration herein.
More accurate models than the COPD‐LUCSS and 
the NLST criteria are needed. Such a model might include 
 variables like socioeconomic status, ethnicity, family history 
of lung cancer and occupational airborne exposure.22 In the 
future, models including genetic or biomarker‐based predic-
tors may lead to further enhancement of lung cancer predic-
tion. The ultimate goal is to create a model that would lead to 
a high number of lung cancers detected by number of persons 
screened and a low number among those not screened. For 
screening tests, it is very important to have high specificity 
and a high NPV. This is to avoid a high number of false nega-
tive results. We are however willing to tolerate a small number 
of false positive results.23 Furthermore, the PPV for both tests 
were 9%‐10%, indicating that only a few of those with positive 
test results actually have the disease. The NPV for both tests 
was 95%‐97% indicating that most of those with a negative 
test will not have lung cancer. However, the PPV and NPV are 
influenced by the prevalence of the disease. The more rare the 
cancer is, the more sure we can be that a negative predictive 
value indicates no abnormality, and the less sure we can be that 
a positive predictive value really indicates an abnormality.24
The discriminative abilities of both the models are poor, 
even when evaluated in the same sample used to fit each 
model. The poor discriminating ability of the COPD‐LUCSS 
and the NLST criteria suggest that these scores might not be 
suitable as screening guidelines. Screening is a large eco-
nomic burden on the health care budgets and one should also 
F I G U R E  1  ROC curve of the COPD‐
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consider the psychological effects of a false positive or a false 
negative result. The NLST screening trial found that 96.4% 
of the positive findings with low‐dose CT were false posi-
tives.2 One might also picture a false feeling of safety among 
patients and doctors regarding those in the low‐risk group.
The strengths of this study are as follows. First, the par-
ticipants were not sampled from a cancer screening trial, 
but from a community‐based sample followed for more than 
4000 person years. Second, the study was prospective in de-
sign. Hence, all the lung cancers were diagnosed after the 
CT scans and examinations were performed. Third, the CT 
scans were assessed for emphysema through a quantitative 
examination, avoiding any observer bias. Finally, the diagno-
ses of lung cancer were obtained from the Cancer Registry of 
Norway which has a near 100% inclusion rate and is based on 
a histologically verified diagnosis of the cancer.
A few limitations should also be mentioned. First, the 
number of lung cancers diagnosed in the study population was 
small. Second, the CT scans were acquired using a high‐reso-
lution CT technique, which was common during the time of the 
data acquisition for this study. However, all the CT scans were 
performed using a standard protocol and the measurements 
of emphysema have been shown to be reproducible using a 
standard protocol.25 Third, the study did not include COPD 
patients diagnosed with GOLD grade 1, which in some studies 
have shown to have the highest incidence of lung cancer.26
Although the COPD‐LUCSS and the NLST criteria were 
associated with increased risk of lung cancer, the AUC values 
show that these models have poor discriminating abilities in 
our cohort of COPD patients. More research is needed in order 
to find better predictive models. The COPD‐LUCSS was not 
significantly better than the NLST criteria in this cohort.
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Methods section of this thesis, 3.3.3 Paper III 
I wrote “An ideal score or model will always be able to classify those who will 
develop the disease in one category, and those who will not develop the disease in 
another. A model’s ability to do just that is called discriminatory ability (95).” This 
is, however, wrong and should have been, “An ideal score or model will always be 
able to classify those who will develop the disease in one category, and those who 
will not develop the disease in another. A model’s ability to do just that can be 
described by both discrimination and calibration. The discriminatory ability of a 
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